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ABSTRACT 
Dihydrodipicolinate synthase (DHDPS) catalyzes the first committed step of L-lysine and 
meso-diaminopimelate biosynthesis, which is the condensation of (S)-aspartate-β-semialdehyde 
(ASA) and pyruvate into dihydrodipicolinate via an unstable heterocyclic intermediate, (4S)-
hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinic acid. DHDPS has been an attractive antibiotic target 
because L-lysine and meso-diaminopimelate are cross-linking components between 
peptidoglycan heteropolysaccharide chains in bacterial cell walls. Studies revealed that mutant 
auxotrophs for diaminopimelate undergo lysis in the absence of diaminopimelate in the medium; 
therefore the assumption is that strong inhibition of DHDPS would result in disruption of meso-
diaminopimelate and L-lysine biosynthesis in bacteria and would stop or decrease bacterial 
growth (eventually leading to bacterial death). In this work, the DHDPS inhibitor design is 
focused on the allosteric site of the enzyme. It was proposed that a compound mimicking binding 
of two L-lysine molecules at the allosteric site at the enzyme’s dimer-dimer interface would be a 
more potent inhibitor than the natural allosteric inhibitor of this enzyme, L-lysine. This inhibitor 
(R,R-bislysine) was synthesized as a racemic mixture, which was then separated with the aid of 
chiral HPLC. The mechanism of feedback inhibition of DHDPS from Campylobacter jejuni with 
its natural allosteric modulator, L-lysine, and its synthetic mimic, R,R-bislysine, is studied in 
detail. It is found that L-lysine is a partial uncompetitive inhibitor with respect to pyruvate and a 
partial mixed inhibitor with respect to ASA. R,R-bislysine is a mixed partial inhibitor with 
respect to pyruvate and a noncompetitive partial inhibitor with respect to ASA, with an inhibition 
constant of 200 nM. Kinetic evaluation of each DHDPS mutants (Y110F, H56A, H56N, H59A 
and H59N) has revealed amino acids responsible for the inhibitory effect of L-lysine, R,R-
bislysine, and we have found that R,R-bislysine is a strong submicromolar inhibitor of Y110F, 
H56A, H56N and H59N. 
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CHAPTER 1.  INTRODUCTION 
1.1 DHDPS as a herbicidal and antibiotic target 
Dihydrodipicolinate synthase (DHDPS) is an enzyme that catalyzes the first committed 
reaction of the lysine biosynthesis pathway in plants, bacteria, and some fungi, which is the 
condensation of pyruvate with (S)-aspartate-β-semialdehyde (ASA) to form (4S)-hydroxy-
2,3,4,5-tetrahydro-(2S)-dipicolinic acid, which then spontaneously dehydrates to (S)-2,3-
dihydropyridine-2,6-dicarboxylate (dihydrodipicolinate) (1-4). There has been ongoing interest 
in DHDPS since the 1960s, and most of the attention was focused on plant and some bacterial 
DHDPS. The plant enzyme allosterically regulates the production of lysine within cells, whereby 
the allosteric modulator of this enzyme is the final product of the biosynthetic pathway, L-lysine. 
Low micromolar IC50 values of lysine are typical for plant DHDPS (5-7). Removal of the 
mechanisms suppressing lysine production in crops would allow for agricultural products with 
higher lysine content and increased nutritional quality. On the other hand, the highly conserved 
sequence of plant DHDPS provides the possibility of designing non-selective herbicides 
targeting DHDPS. While some progress was achieved to engineer crops insensitive to lysine 
regulation by modification of the allosteric site of the enzyme, there are no compounds to date 
that are able to inactivate DHDPS and work as herbicides. 
Bacterial DHDPS have less sequence identity than plant DHDPS. The importance of lysine 
feedback inhibition in bacteria remains unclear; IC50 values of lysine range from micromolar and 
millimolar level for some DHDPS from Gram-negative bacteria (8-10) to fully insensitive to 
lysine inhibition for some enzymes from Gram-positive bacteria (11, 12). The lysine biosynthesis 
pathway is essential for bacteria; it produces L-lysine for protein biosynthesis and meso-
diaminopimelate, an essential component of bacterial cell walls (13). Bacterial strains with a 
deleted dapA gene (encoding DHDPS) are not viable and undergo lysis in the absence of meso-
diaminopimelate in the medium (14-16). DHDPS has an additional significance for sporulating 
bacteria. The product of the reaction catalyzed by DHDPS, dihydrodipicolinate, is a precursor for 
dipicolinate which can comprise up to 15% of dry weight of bacterial spores (17, 18). Mutants 
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lacking DHDPS are not able to sporulate without supplementation of the cultures with 
dipicolinate (18). The absence of this lysine biosynthetic pathway in humans and its necessity for 
bacteria make DHDPS an attractive target for drug development (19). 
1.2 Structure of DHDPS 
1.2.1 Active site and proposed catalytic mechanism 
DHDPS from many species exists as a homotetramer in solution (7, 20-22), however dimeric 
forms also occur (23, 24). The monomer has a TIM barrel fold, a common versatile fold 
observed in many enzymes (25), consisting of eight α-helices and eight parallel β-strands (26). 
The N-terminal domain of DHDPS forms an 8-fold α/β barrel structure connected to the α-helical 
C-terminal domain (26). The active site of the enzyme is at the C-terminal ends of the β-strands, 
where one of the loops forms a short helix with a highly conserved Arg138 (in E. coli DHDPS) 
whose side-chain is situated over the β-barrel. The active site of DHDPS consists of the key 
residue, lysine, which forms a Schiff base with the first substrate, pyruvate, and a catalytic triad, 
threonine and two tyrosines, which is proposed to act as a proton relay, transferring protons to 
and from the active site (27). One of the tyrosines in the catalytic triad belongs to a chain of the 
adjacent monomer (Figure 1.1). DHDPS from E. coli is a homotetramer, which consists of a pair 
of “tight dimers” (28). A number of crystal structures of DHDPS from different species are 
available in the Protein Data Bank (PDB). 
3 
 
 
Figure 1.1  Active site of DHDPS. Crystal structure of Campylobacter jejuni DHDPS, PDB 
ID 3LER. E. coli numbering is shown in blue. K166 forms a Schiff base with pyruvate, while 
Y137, T47 and Y111' form the catalytic triad. Y111' belongs to the adjacent monomer (shown in 
green).  
The proposed mechanism of DHDPS (Scheme 1.1) first involves binding of pyruvate in the 
active site and formation of a Schiff base with lysine, followed by deprotonation to the enamine. 
The second substrate, ASA, binds and reacts with the enamine, which then cyclizes into an 
unstable heterocyclic product, (4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinic acid (HTPA) 
(27, 28). HTPA can spontaneously dehydrate into dihydrodipicolinate or enter the next 
enzymatic step of the pathway, reduction (with dehydration), catalyzed by dihydrodipicolinate 
reductase (DHDPR) (2). Most of details of the proposed mechanism have not been determined 
experimentally. Involvement of specific residues in the mechanism has been inferred from 
protein crystallography (1, 10) and site-directed mutagenesis experiments (27, 29). Proton 
transfer from ASA to Gly186 is an alternative and arguably more likely mechanism. 
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Scheme 1.1  Currently accepted mechanism of DHDPS from E. coli (27, 28).  
 
1.2.2 Allosteric site and putative mechanisms of signal transduction 
The allosteric site of DHDPS is located at the interface of the monomers forming each tight 
dimer in the tetramer. Lysine binding pockets are situated side by side on each monomer, 
forming a large regulatory site, where amino acid residues of both adjacent monomers are 
involved in binding of each molecule of lysine. The crystal structures of DHDPS with lysine 
bound at the allosteric site have been obtained for several species (Arabidopsis thaliana, C. 
jejuni, E. coli, Pseudomonas aeruginosa, Vitis vinifera,), and residues responsible for lysine 
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coordination are known for these DHDPS (8, 22, 28, 30, 31). The allosteric site of C. jejuni 
DHDPS is shown in Figure 1.2. Each molecule of lysine makes hydrogen bonds with Ser51, 
Ala52, Leu54, His59, Tyr110, Asn84', and Glu88', while His56 forms a cation π-interaction with 
the ε-amino group of lysine (the amino acid residues indicated with a prime belong to the 
adjacent monomer). The most conserved residues in the allosteric site of all DHDPS are Tyr110 
and Asn84'. Despite the sequence divergence among bacterial DHDPS, including allosteric site 
residues, the architecture of allosteric sites of DHDPS from different species is very similar.  
 
Figure 1.2  The allosteric site of DHDPS from C. jejuni (4M19). The residues of monomers 
A and B are shown in yellow and green, respectively. The active site residues Y111', T47, Y137 
and K166 as a Schiff base are also shown for each monomer.  
The exact mechanism of signal transduction from allosteric site to active site is not yet 
completely understood, although available crystal structures and molecular dynamics simulations 
allow us to propose a mechanism of allosteric regulation. The carboxylic group of the allosteric 
lysine creates a hydrogen bond with the phenolic OH of Tyr110, altering its position. This 
Tyr110 movement promotes a shift of Tyr111, which is a residue of the catalytic triad, and 
therefore its displacement causes a reduction in catalytic effectiveness within the active site. 
Furthermore, according to Atkinson et al. (who studied V. vinifera DHDPS), Tyr131 (equivalent 
of Tyr110 in C. jejuni) forms a hydrophobic stack with the catalytic triad residue Tyr132' 
(Tyr111' in C. jejuni) (22). This stack is disrupted upon lysine binding, displacing the hydroxyl 
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group of Tyr132' (Tyr111' in C. jejuni) and slowing down or discontinuing function of the 
catalytic triad. 
1.3 Feedback inhibition of DHDPS by lysine in bacteria and plants 
1.3.1 Kinetic models of lysine inhibition 
Most DHDPS display partial lysine inhibition (32), meaning residual activity remains at 
saturating concentrations of lysine, although there are a few examples of plant DHDPS where 
full lysine inhibition was observed (33). The mechanism of lysine inhibition remains 
controversial, due to the contradictory nature of reported inhibition results. Various research 
groups have reported different mechanisms of lysine inhibition, for instance: it is a competitive 
inhibitor with respect to ASA and a noncompetitive inhibitor with respect to pyruvate (5); it is a 
competitive inhibitor versus pyruvate and mixed inhibitor with respect to ASA (7); it follows an 
uncompetitive partial mechanism with respect to pyruvate at pH 8 and mixed partial model of 
inhibition at low pH (34); it is a mixed partial inhibitor with respect to pyruvate and 
noncompetitive partial inhibitor with respect to ASA (10, 22), etc. Moreover, despite the known 
fact that lysine binds cooperatively to DHDPS (5, 6, 22, 34-36), cooperativity coefficients have 
not been taken into account while fitting kinetic models to experimental data, until the recent 
report of Atkinson et al. (22) and this present work (8).  
1.3.2 DHDPS lacking lysine inhibition 
All known plant DHDPS are sensitive to lysine inhibition, and this it is one of the reasons 
why unmodified crops do not accumulate lysine. To improve the nutritional value of crops, a 
number of research groups are working on the problem of increasing the lysine content in crops. 
A number of crops were genetically engineered to increase lysine levels by expressing bacterial 
DHDPS (lysine-insensitive or reduced lysine sensitivity). For some crops, the desired result has 
been achieved (37, 38), while other transgenic plants do not accumulate lysine in high 
concentrations, which is likely due to the existence of downregulation mechanisms of utilizing 
excess of lysine (39).  
Certain mutations in the allosteric site can make DHDPS less sensitive or insensitive to lysine 
inhibition. For example, substitution of Trp53 (His53 in E. coli, His56 in C. jejuni) with Arg 
makes A. thaliana totally insensitive to lysine feedback inhibition (33). Mutations S157N, 
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E162K, A166T and A166V in Zea mays DHDPS (A79, E84 and L88, respectively, in E. coli) 
also make this enzyme insensitive to lysine (40). Maize cells transformed with a plasmid bearing 
the A166V mutated DHDPS maize gene resulted in increased lysine accumulation in this crop 
(41).  
DHDPS from Gram-positive bacteria are weakly inhibited or insensitive to lysine. The reason 
for this is in variations in the allosteric site sequence, whereby the amino acid composition is 
unfavorable for lysine binding. For instance, Lys or Arg in position 56 creates a clash of positive 
charges with the side chain of the allosteric lysine, therefore preventing binding. DHDPS from 
Gram-positive Corynebacterium glutamicum has Lys in position 56, and is insensitive to lysine 
feedback inhibition, making this organism useful for industrial production of L-lysine (42). 
Staphylococcus aureus, known for its resistant strains to front-line antibiotics, contains dimeric 
DHDPS (24). This enzyme has Lys in positions 56 and 84, which makes the allosteric site 
shallow and changes the charge distribution in the binding pockets, and, as a result, this enzyme 
is insensitive to lysine inhibition (24). The design of inhibitors targeting the allosteric site of 
Gram-positive lysine-insensitive DHDPS seems to be an especially challenging task. 
1.4 Inhibitors of DHDPS targeting the active site and the allosteric site 
Most research groups working on inhibitors of DHDPS focus their attention on the active site. 
There are a few weak inhibitors that have been shown to be competitive with respect to ASA, 
such as succinate β-semialdehyde (1), and with respect to pyruvate, such as 2-ketobutyrate, 2-
ketovalerate, 3-fluoropyruvate and glyoxalate (34). Several inhibitors of DHDPS are shown in 
Figure 1.3 and given in Table 1.1. Product mimics such as dipicolinic 1.1 and chelidamic 1.3 
acids are weak millimolar inhibitors (34, 43). Interestingly, inhibition of growth of the late blight 
fungus Phytophthora infestans by millimolar concentrations of dipicolinic and chelidonic acids 
1.1 and 1.2 was observed in vivo using infected potato leaf discs (44). Moderate inhibition of E. 
coli growth was observed for the piperidine diester 1.4 and chelidamic 1.3 acid at 20 mM (45). 2-
Ketopimelic acid was found to be a weak irreversible inhibitor (1), and based on this 
observation, several compounds mimicking the acyclic enzyme-bound condensation product of 
ASA and pyruvate have been proposed (46). Two of them, bis(keto-acid) 1.5 and bis(oxime-
ester) 1.6, showed higher potency and the constrained acyclic-intermediate model was selected 
as a potential inhibitor lead (46). The continuation of that work was synthesis of phenolic 
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ketoacid derivatives 1.9 and 1.10, which condense with the enzyme in a time-dependent manner 
(47). Analogs of 4-oxo-heptenedioic acid 1.7 and 1.8 proved to be irreversible millimolar 
inhibitors of DHDPS (48).  
A number of millimolar inhibitors targeting the allosteric site of the enzyme have also been 
reported. Among them are homoserine lactone, 2-aminocyclopentanone, (S)-glutamic acid, (S)-
aspartic acid (49), and S-(2-aminoethyl)-L-cysteine (thialysine), a sulfur-containing lysine mimic. 
Interestingly, despite a high structural similarity to L-lysine, thialysine binds ten times weaker to 
E. coli DHDPS than lysine (34). 
 
Figure 1.3  Inhibitors targeting the active site of DHDPS.  
 
Table 1.1  Inhibitors targeting the active site of DHDPS. 
Compound Inhibition parameter Organism Reference 
1.1 Ki 11 mM wrt pyr; 18 mM wrt ASA E. coli (34, 43) 
 1 mM decrease activity by 75% P. infestans (44) 
1.2 1 mM decrease activity by 54% P. infestans (44) 
1.3 IC50 22 mM  E. coli (43) 
1.4 IC50 20 mM E. coli (43) 
1.5 Ki
app
 2.96 mM E. coli (46) 
1.6 Ki
app
 0.33 mM E. coli (46) 
1.7 Ki
app
 4.95 mM E. coli (48) 
1.8 Ki
app
 1.63 mM E. coli (48) 
1.9 Ki
app
 11.8 mM E. coli (47) 
1.10 Ki
app
 12.0 mM E. coli (47) 
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1.5 Proposal and research objectives 
The main goal of this research is to find a potent inhibitor of DHDPS targeting the allosteric 
site. The attention of most research groups studying DHDPS is focused on inhibitors binding at 
the active site, and, aside from random inhibitor screening, no attempts have been made to 
develop an inhibitor to specifically target the allosteric site. The allosteric site was chosen as a 
target because noncompetitive inhibitors cannot compete with the substrates as competitive 
inhibitors do, so pyruvate and ASA inside the cell would not interfere with allosteric inhibitors. 
Until now there have been no known noncompetitive inhibitors stronger than the natural 
inhibitor L-lysine, and part of this project is to determine if it is possible to find a better inhibitor 
than L-lysine. Given the architecture of the allosteric site, it is possible for one molecule of 
inhibitor to fill two lysine binding pockets at the interface of adjacent monomers in the enzyme, 
so that only two inhibitor molecules would bind to the tetrameric enzyme. This strategy would 
decrease the entropy of binding of the inhibitor and increase the change of entropy of the system, 
which can lead to an overall decrease in free energy of the system (Equation 1.1). 
ΔG = ΔH – TΔS              (1.1) 
 
Phenix and Palmer (36) studied the binding of lysine to DHDPS from Sinorhizobium meliloti 
using ITC, and they concluded that lysine binds to the enzyme in a highly cooperative manner, 
where the first molecule of lysine binds loosely and the second one binds so tightly, that binding 
would be nearly simultaneous. The core of this proposal is that a molecule mimicking binding of 
two lysines will have higher affinity to the enzyme and will be a more potent inhibitor than 
lysine. The crystal structure of E. coli DHDPS (1YXD) with two lysines bound at the allosteric 
site provides a distance of 4.1 Å between the α-carbons of the two lysines. A two-carbon bridge 
would perfectly fit the space between the α-carbons, resulting in a structure of “R,R-bislysine” 
shown in Figure 1.4.  
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Figure 1.4  Structure of R,R-bislysine.  
Here, we use DHDPS from Campylobacter jejuni as a model enzyme for assaying inhibitors. 
C. jejuni is a Gram-negative pathogen causing mostly gastroenteritis in humans, although more 
severe symptoms can also occur (50, 51).  DHDPS from C. jejuni shares 37% sequence identity 
with E. coli DHDPS and two crystal structures are available in the Protein Data Bank (3LER and 
3M5V). 
The research objectives of this study are: 
 Clone dapA and dapB genes from C. jejuni genomic DNA into the vector pQE-80L and 
transform E. coli XL1-Blue strain with this recombinant plasmid; 
 Express and purify recombinant DHDPS and DHDPR; 
 Kinetically evaluate DHDPS from C. jejuni using the coupled DHDPS-DHDPR assay; 
 Determine the kinetic mechanism of lysine inhibition and calculate inhibition parameters; 
 Synthesize R,R-bislysine and test its efficacy against C. jejuni DHDPS; 
 Determine the kinetic mechanism of R,R-bislysine inhibition and calculate inhibition 
parameters; 
 Perform site-directed mutagenesis on selected residues in the allosteric site to correlate 
structural changes of the protein with changes in binding affinity of the enzyme for the 
noncompetitive inhibitors; 
 Examine the effectiveness of using the allosteric site of DHDPS as a target for 
development of new noncompetitive inhibitors. 
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1.6 Contributions of the author to the work presented in this thesis 
Description of candidate’s contribution to the manuscript (Chapter 2) 
CHAPTER 2.  Dihydrodipicolinate synthase from Campylobacter jejuni: Kinetic mechanism of 
cooperative Allosteric Inhibition and Inhibitor-Induced Substrate Cooperativity. 
This chapter is an exact copy of a paper published in Biochemistry. Reprinted with permission 
from: Skovpen, Y. V., and Palmer, D. R. (2013) Dihydrodipicolinate synthase from 
Campylobacter jejuni: kinetic mechanism of cooperative allosteric inhibition and inhibitor-
induced substrate cooperativity, Biochemistry 52, 5454-5462. Copyright (2013) American 
Chemical Society. 
For this contribution, I performed all the experimental work: cloning of the genes, expression 
and purification of the proteins, synthesis of (S)-aspartate-β-semialdehyde and all kinetic 
experiments. I performed data analysis, results interpretation and wrote the initial draft of the 
work. Dr. David Palmer provided extensive guidance throughout the experimental work, 
supervised results interpretation, and was greatly involved in writing and editing the paper. 
Description of candidate’s contribution to the thesis (except Chapter 2) 
In the rest of the thesis, all experimental work was performed by the candidate except: 
 DHDPS mutant Y110F was generated by Shuo Li; 
 preliminary kinetic experiments with H56A and H56N were performed by Shuo Li;  
 crystal structures of C. jejuni DHDPS referred to throughout the text were generated by 
Cuylar Conly, supervised by Dr. David Sanders. 
All experiments described in this thesis were part of the thesis work.  
The co-author of the manuscript constituting Chapter 2, Dr. David Palmer, agrees that his 
contributions be included in this thesis, and with the description of his contributions. Other work 
referred to in the thesis performed by Shuo Li and Cuylar Conly is done so with their permission, 
and with that of their supervisors, Professor David Palmer and Professor David Sanders. 
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CHAPTER 2.  DIHYDRODIPICOLINATE SYNTHASE FROM 
CAMPYLOBACTER JEJUNI: KINETIC MECHANISM OF COOPERATIVE 
ALLOSTERIC INHIBITION AND INHIBITOR-INDUCED SUBSTRATE 
COOPERATIVITY 
2.1 Permission to use this manuscript 
Skovpen, Y. V., and Palmer, D. R. (2013) Dihydrodipicolinate synthase from Campylobacter 
jejuni: kinetic mechanism of cooperative allosteric inhibition and inhibitor-induced substrate 
cooperativity, Biochemistry 52, 5454-5462. Copyright (2013) American Chemical Society. 
This work fits naturally as a separate chapter prior to the remaining chapters of the thesis on 
novel inhibitor design, synthesis, and evaluation (Chapter 3); and on the generation, 
characterization, and inhibition of site-directed mutants (Chapter 4). A final chapter giving a 
discussion, conclusions, and future directions of the sum of the work will also be included. 
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2.2 Abstract  
Dihydrodipicolinate synthase (DHDPS), an enzyme of the meso-diaminopimelate pathway of 
lysine biosynthesis, is essential for bacterial growth and is considered a target for novel 
antibiotics. We have studied DHDPS from Campylobacter jejuni for the first time, determining 
the kinetic mechanism of catalysis and inhibition with its natural allosteric feedback inhibitor, 
(S)-lysine. The tetrameric enzyme is known to have two allosteric sites, each of which binds two 
molecules of lysine. The results suggest that lysine binds highly cooperatively, and primarily to 
the F form of the enzyme during the ping-pong mechanism. By applying graphical methods and 
nonlinear regression, we have discriminated between the possible kinetic models and determined 
the kinetic and inhibition constants and Hill coefficients. We conclude that (S)-lysine is an 
uncompetitive partial inhibitor with respect to its first substrate, pyruvate, and a mixed partial 
inhibitor with respect to its second substrate, (S)-aspartate-β-semialdehyde (ASA), which differs 
from the kinetic models for inhibition reported for DHDPS from other sources. The Hill 
coefficients for the binding of lysine to different forms of the enzyme are all greater than 2, 
suggesting that the two allosteric sites are not independent. It has been found that ASA binds 
cooperatively in the presence of (S)-lysine and the cooperativity of binding increases at near-KM 
concentrations of pyruvate. The incorporation of Hill coefficients into the kinetic equations was 
crucial for determining the kinetic model for this enzyme. 
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2.3 Introduction  
Dihydrodipicolinate synthase (DHDPS, E.C. 4.2.1.52) is an allosterically regulated enzyme of 
the bacterial meso-diaminopimelate pathway, responsible for condensation of (S)-aspartate-β-
semialdehyde (ASA) and pyruvate into an unstable heterocyclic product (4S)-hydroxy-2,3,4,5-
tetrahydro-(2S)-dipicolinic acid (1, 2), which spontaneously dehydrates to (S)-2,3-
dihydropyridine-2,6-dicarboxylate (dihydrodipicolinate) (2-4) (Figure 2.1). The reaction has 
been shown to follow a ping-pong, or "substituted-enzyme" mechanism, whereby pyruvate 
condenses with an active site lysine residue of the native or "E" form of the enzyme. This 
substituted or "F" form binds ASA and a new carbon-carbon bond is formed via an aldol 
reaction. The ligated intermediate then cyclizes by transimination and is released from the active 
site. 
 
Figure 2.1  Reaction catalyzed by DHDPS. In the case of C. jejuni DHDPS, the active-site 
lysine residue is Lys166.  
DHDPS is an attractive antibiotic target because (S)-lysine and meso-diaminopimelic acid are 
cross-linking components between peptidoglycan heteropolysaccharide chains in bacterial cell 
walls (5, 6). The activity of DHDPS can be affected by inhibitor molecules binding at the active 
or the allosteric site of the enzyme. A number of compounds targeting both active and allosteric 
sites have been proposed and described in the literature (7-13), but effective inhibitors of 
DHDPS have not yet been reported. In order to design an effective allosteric modulator of 
DHDPS, it is necessary to clarify the mechanism of allosteric interaction of DHDPS with its 
natural allosteric inhibitor (S)-lysine. There are several reports describing lysine inhibition of 
DHDPS isolated from different species, such as plants (12, 14, 15) and Gram-negative bacteria 
(16, 17), which are inhibited at very low concentrations of lysine, and Gram-positive bacteria 
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(18-20), which are weakly inhibited or insensitive to lysine. Despite this level of scrutiny, the 
kinetic mechanism of lysine inhibition is still not clear. Early papers using the wheat enzyme 
reported that lysine is a competitive inhibitor with respect to ASA and a noncompetitive inhibitor 
with respect to pyruvate (12). On the contrary, Frisch et al. reported that lysine is a competitive 
inhibitor versus pyruvate and mixed inhibitor with respect to ASA using the DHDPS from maize 
(15). Laber et al. described the mechanism of lysine inhibition of E. coli DHDPS as partial (13), 
which is in agreement with subsequent reports. Karsten (21), also working with the E. coli 
enzyme, determined that lysine binds to the F form of the enzyme at pH 8, suggesting an 
uncompetitive partial mechanism with respect to pyruvate. In the same article he showed that 
lysine can bind to the E form of the enzyme at low pH, which is an indication of a mixed model 
of inhibition. Over the last decade, research groups, particularly Gerrard and co-workers, have 
been describing the lysine inhibition mechanism as "partial mixed" with respect to pyruvate and 
"noncompetitive partial" with respect to ASA (17), except in the report of Soares da Costa et al. 
that defines the inhibition type as "partial uncompetitive" with respect to pyruvate (22). Atkinson 
et al. (23) also reports ''mixed partial'' and ''noncompetitive partial'' inhibition with respect to 
pyruvate and ASA respectively for the common grapevine DHDPS. 
With the aid of isothermal titration calorimetry, it was shown that lysine binds cooperatively 
displaying a cooperative partial mixed model with respect to pyruvate for E. coli DHDPS (24), 
and lysine was also observed to bind to the E form of S. meliloti DHDPS (25). Importantly, the 
cooperative mode of lysine binding has been known as early as 1987 (12), but only a few authors 
reported cooperativity coefficient values (12, 14, 21, 23), and the cooperativity of binding is not 
accounted for in kinetic analyses. This may account for the variation in interpretation of kinetic 
data for DHDPS; although the determination of Hill coefficients and their incorporation into 
kinetic analyses makes the analysis more complex, it is likely an essential component for 
determining the best kinetic model of lysine inhibition. (As this manuscript was being prepared, 
Atkinson et al. (23) incorporated cooperativity coefficients for lysine binding derived from a 
nonlinear fit to kinetic models).  
Here we report a kinetic analysis of the catalyzed reaction and its allosteric inhibition for the 
recombinant hexahistidine-tagged DHDPS from Campylobacter jejuni. C. jejuni is a Gram-
negative pathogen that can cause gastroenteritis in humans, and can also lead to severe 
conditions such as Guillain-Barré syndrome, meningitis, and chronic colitis (26, 27). Sequence 
19 
 
alignment (28, 29) reveals that C. jejuni DHDPS shares 37% sequence identity with E. coli 
DHDPS. Kinetic parameters and lysine inhibition constants of C. jejuni DHDPS have not yet 
been reported, but X-ray crystal structures of C. jejuni DHDPS in the E form (RCSB Protein 
Data Bank ID 3M5V) and in the pyruvate-modified F form (PDB ID 3LER) have been 
deposited. These structures show conservation of the tertiary and quaternary structure: a (α/β)8 
"TIM" barrel monomer forms a tetramer consisting of a loosely-associated dimer of more 
intimately connected dimers. Each ''tight dimer'' contains an allosteric regulatory site at the 
interface of the two monomers, and within these dimers each monomer contributes a tyrosine 
residue to the active site of the other. All active-site residues identified in DHDPS from other 
species are present in the C. jejuni DHDPS structure, as are the residues responsible for lysine 
binding at the allosteric site (30) which have been determined as a result of the crystal structure 
of E. coli DHDPS with bound lysine molecules (PDB ID 1YXD). As described herein, the 
surprisingly high affinity for lysine makes a thorough characterization of the cooperative 
allosteric inhibition of this enzyme an instructive model for discriminating between kinetic 
models for this and other complex enzymatic processes. 
2.4 Materials and methods 
2.4.1 ASA synthesis 
ASA was synthesized according to the reported procedure (31). Due to the hygroscopic 
properties of ASA, the concentration of each newly prepared work solution of ASA was 
determined using the DHDPS-DHDPR coupled kinetic assay described below, in the presence of 
excess NADH.  
2.4.2 Cloning of the dapA and dapB genes 
C. jejuni genomic DNA was prepared by Dr. Bonnie Chaban, Western College of Veterinary 
Medicine, University of Saskatchewan. The dapA and dapB genes (encoding DHDPS and 
dihydrodipicolinate reductase (DHDPR) respectively) were PCR-amplified from genomic DNA 
using KAPA HiFi DNA polimerase (Kapa Biosystems) and forward and reverse primer pairs  
5’-GAAAGGGGATCCATGGATAAAAATATTATCATTGGGGC -3’,  
5’-ATTCTGCTGCAGTTAAAATCCTTTGATCTTATATTTTTTCATCACTTC-3’ 
respectively for dapA; 5’- TCAAGGGGATCCATGATTAAAATAGGAATTTATGGCG -3’,  
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5’-ACTGCACTGCAGTTAAATTCCTAAAAAATCATTGATTGAATAC-3’ respectively for 
dapB. 
Each pair of genes was ligated into a pQE-80L vector (Qiagen) as BamHI/PstI restriction 
fragments using T4 DNA-ligase (New England BioLabs). Then E. coli XL1-Blue competent 
cells were transformed with the plasmids. Colonies containing correct recombinant plasmids 
were identified by analysis of restriction enzymes products, and positive candidates were 
sequenced by the DNA Technologies Unit of the National Research Council, Saskatoon, Canada.  
2.4.3 Expression and purification of enzymes 
TB media (32) (250 mL) containing ampicillin (50 µg/mL) was inoculated with a single 
colony of E. coli XL1-Blue cells containing recombinant plasmid pQE-80L with dapA or dapB 
genes, and incubated with shaking at 37 °C until cultures reached an OD600 of 0.5 - 0.6. Protein 
expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside to a final 
concentration 0.5 mM. The cell culture was incubated with shaking (250 rpm) at 15 °C for 15 h, 
and then centrifuged at 5,180 × g for 30 min. The resulting cell pellet was resuspended in 10 ml 
of binding buffer (20 mM Tris-HCl, 5 mM imidazole, 500 mM NaCl, 12.5% glycerol, pH 7.9) 
and sonicated using a Virsonic 600 Ultrasonic Cell Disrupter (VirTis). The sample was chilled in 
an ice bath during all manipulations. The crude lysate was separated from cell debris by 
centrifugation at 27,000 × g for 30 min at 4 °C. The supernatant containing DHDPS or DHDPR 
was filtered through a 0.45 μm syringe filter and loaded onto a 1 ml HiTrapTM IMAC FF column 
(GE Healthcare), prepared according to the manufacture's procedure and equilibrated with 5 ml 
of binding buffer. The column was washed with 5 ml of binding buffer, a 1:1 mixture of binding 
and washing (20 mM Tris-HCl, 60 mM imidazole, 500 mM NaCl, 12.5% glycerol, pH 7.9) 
buffers, 10 ml washing buffer, a 1:1 mixture of binding and stripping (20 mM Tris-HCl, 500 mM 
NaCl, 100 mM EDTA, 12.5% glycerol, pH 7.9) buffers, then 15 ml of stripping buffer. Fractions 
were analyzed by SDS-PAGE, and those containing purified enzyme were pooled and dialyzed 
at 4 °C for 24 h in storage buffer (20 mM Tris-HCl, 100 mM NaCl, 1 mM DTT, 40% glycerol, 
pH 7.9). The resulting proteins were concentrated to 0.37 mg/ml for DHDPS and 1.43 mg/ml for 
DHDPR using an Amicon Ultra-15 Centrifugal Filter (30 kDa MWCO, EMD Millipore). 
Enzyme concentrations were determined by NanoDrop
®
 ND-1000 using calculated parameters 
(ProtParam) (33) (molecular weight and extinction coefficient) for DHDPS (MW 34069 Da, ε280 
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= 18068 M
-1
cm
-1) and for DHDPR (MW 28094 Da, ε280 = 15930 M
-1
cm
-1
). The proteins were 
aliquoted and stored at -80 °C. 
2.4.4 Enzyme assays 
The activity of DHDPS was measured using a coupled assay (3). The initial velocity of the 
DHDPS enzymatic reaction was determined by monitoring the decrease in absorbance at 340 nm 
due to oxidation of NADH (ε340 = 6220 M
-1
cm
-1
). All kinetic measurements were performed on a 
Beckman DU640 spectrophotometer at 25 °C maintained by circulating water bath. Only freshly 
prepared solutions of substrates were used in the assay. All measurements were made using 100 
mM HEPES buffer at pH 8.0. A typical assay contained 0.16 mM NADH, 0.37 μg of DHDPS, 
7.15 μg DHDPR and varying concentrations of ASA (0.06 - 2.24 mM) and pyruvate (0.12 – 3.50 
mM). The excess amount of DHDPR was determined experimentally, to ensure that the DHDPS-
catalyzed reaction would be rate-limiting. A 0.01M solution of (S)-lysine was used in inhibition 
experiments. Cuvettes containing the assay mixture were incubated for three minutes to 
equilibrate at 25 ºC before the reaction was triggered by the addition of DHDPS. The obtained 
kinetic data were fitted to the rate equations 2.1 - 2.4 using SigmaPlot
®
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where Vmax is the maximum velocity, KM(A) and KM(B) are the Michaelis-Menten constants for 
two substrates, A and B are the concentrations of the substrates, v is the initial velocity. Ki is the 
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inhibition constant, I is the inhibitor concentration, S is the substrate concentration, KS is the 
dissociation constant of the ES complex, n is the Hill coefficient for ASA (when applicable), α 
and β are proportionality constants, and h and h' are Hill coefficients for lysine where, depending 
on the substrate being bound, h' and h are cooperativity coefficients for lysine binding to E and 
E:pyr or F and F:ASA forms of enzyme respectively in Equation 2.2. Equation 2.1 is a rate 
equation for the ping-pong bi-bi mechanism, Equations 2.2 - 2.4 describe mixed partial, 
uncompetitive partial and noncompetitive partial mechanisms of inhibition respectively, to 
which the Hill coefficients, h, h' and n, have been introduced. The experiments were conducted 
by varying concentration of one substrate while concentration of another was saturating or at 
near-KM concentration. 
Equation 2.5 is the Hill equation for partial inhibition,  
IhK
vv
vv
i
satii
logloglog
0
)(



             (2.5) 
where vi is the velocity in the presence of the inhibitor, v0 is the velocity in the absence of the 
inhibitor, vi(sat) is the reaction velocity at saturating concentrations of inhibitor, and K is an 
apparent overall dissociation constant. For reactions in which the second substrate was at near-
KM concentration, vi(sat) was measured at [I] = 1.0 mM; for reactions in which the second 
substrate was at saturating concentration, vi(sat) was measured at [I] = 2.0 mM. 
2.5 Results 
2.5.1 Ping-pong mechanism 
The kinetic mechanism of catalysis by recombinant histidine-tagged DHDPS from C. jejuni 
was assessed using the DHDPR-coupled assay described above. Note that DHDPR is not 
selective, in that it can utilize both NADPH and NADH; the latter was used for kinetic studies of 
DHDPS. Variation of the concentrations of each substrate in the presence of DHDPS and 
DHDPR resulted in double-reciprocal plots displaying parallel lines, consistent with the 
canonical ping-pong kinetic mechanism observed for DHDPS from other sources. (Supporting 
information, Figure S2.1, Figure S2.2). The kinetic constants are shown in Table 2.1. 
Substrate inhibition by ASA, which has been reported for DHDPS from some sources and/or 
with some ASA preparations (17), was not observed. The kinetic constants of C. jejuni DHDPS 
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at the chosen assay conditions (25 °C, pH 8.0, 100 mM HEPES) are close to those of E. coli 
DHDPS (17, 34). No evidence for significant cooperativity of substrate binding was observed.  
Table 2.1  Kinetic constants for C. jejuni DHDPS 
KM(pyr) KM(ASA) kcat kcat/KM(pyr) kcat/KM(ASA) 
0.35 ± 0.02 mM 0.16 ± 0.01 mM 76 ± 1 s-1 (2.2 ± 0.1) × 105 M-1s-1 (4.8 ± 0.3) × 105 M-1s-1 
 
2.5.2 Lysine inhibition 
C. jejuni DHDPS is strongly inhibited by lysine. A simple observation of the dependence of 
rate on lysine concentration at fixed substrate concentrations indicates an apparent IC50 value 
near 65 µM. (Figure 2.2). DHDPS from Gram-negative bacteria can be weakly, moderately or 
strongly inhibited by lysine showing IC50 values from micromolar to millimolar range: 53 µM 
for N. meningitidis (16), 0.2 mM for E. coli (35), and 0.7 mM for S. meliloti (36). Figure 2.2 also 
reveals two other important features of inhibition. First, the shape of the curve indicates 
significant cooperativity of inhibition. Second, there is approximately 10% residual activity at 
saturating high concentrations of lysine under conditions employed. This partial inhibition (or 
"hyperbolic" inhibition) is also typical of DHDPS from other sources (13, 16, 17). 
 
  
Figure 2.2  Lysine inhibition of DHDPS activity at 0.16 mM ASA and 3.5 mM pyruvate.  
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2.5.3 Calculation of cooperativity coefficient for lysine 
A series of Hill plots were built over the range from 0.02 to 0.2 mM of lysine, where Hill 
plots have minimal deviation from linearity and cooperativity (slopes of Hill plots) can be 
considered constant. Experimentally-obtained Hill plots are normally not linear and their 
curvature indicates a mixture of positive and negative cooperativity (37). By analyzing the shape 
of Hill plots it is possible to estimate values of the four intrinsic association constants for the four 
binding steps of the ligand to the tetramer (37). When the concentration of inhibitor is low, the 
complexes with a low value of the Hill coefficient (h) do not contribute significantly to the initial 
velocity; on the other hand, at high concentrations of the inhibitor it becomes difficult to 
distinguish small changes in the velocity (38). Because the inhibition is partial, the logarithm of 
the ratio ''inhibitable activity'' in the presence and absence of lysine is plotted versus the 
logarithm of lysine concentration (Equation 2.5). Values of h are the slopes of the Hill plots. As 
seen in Figure 2.3, data collected at concentrations of lysine ≤0.1 mM give a straight line, but at 
higher concentrations the plot deviates from linearity as if values of h were approaching unity, 
i.e. cooperativity appears to dissipate at very high occupancy of the inhibitory sites. If this were 
the case, it would manifest itself in biphasic behavior evident from double-reciprocal plots over a 
wide range of concentrations of lysine. 
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Figure 2.3  Relationship between degree of cooperativity and concentration of inhibitor. Solid 
line: linear area (lysine concentration 0.02 – 0.2 mM). Dashed line: apparent decrease in 
cooperativity at high lysine concentrations (≥ 0.2 mM). Data obtained at constant concentration 
of pyruvate 0.35 mM, 0.072 mM ASA () and 2.0 mM ASA ().   
Results of previous studies of DHDPS inhibition kinetics have differed in some details, but 
consistently have shown that the presence of pyruvate results in tighter binding of lysine to the 
allosteric site, suggesting that the condensation of pyruvate in the active site somehow alters the 
nature of the inhibitory site. Because of this, we felt that the degree of cooperativity of lysine 
binding need not be the same at all substrate concentrations. We therefore conducted 
experiments to determine cooperativity whilst varying the concentration of each substrate in the 
presence of both saturating and near-KM concentrations of the other substrate (Supporting 
information, Figure S2.3, Figure S2.4, Figure S2.5, and Figure S2.6). When the concentration of 
either substrate was varied in the presence of saturating concentration of the other, the average of 
h was found to be 2.8  0.2 for both cases. When ASA was maintained at near-KM concentration 
(0.18 mM), the value of h averaged 3.0  0.2, and when pyruvate was held at near-KM 
concentration (0.35 mM), h = 2.3  0.4. The difference in value at low concentration of pyruvate 
suggests that this substrate is affecting the cooperativity of lysine binding, and is consistent with 
a kinetic mechanism in which pyruvate binds to the enzyme before lysine does. Drawing 
conclusions about the kinetic mechanism based on Hill coefficients should be done with caution, 
however, due in part to experimental error inherent in the calculation of h. 
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2.5.4 Relationship of substrate and inhibitor binding 
Using these Hill plots, we determined the IC50 of lysine under a range of conditions. From 
Equation 2.5, when vi = 0.5v0, the ordinate equals log((0.5v0 - vi(sat))/(v0 - 0.5v0)) or, after 
rearranging, log(1 - (2vi(sat)/v0)). The projection of the ordinate log(1 - (2vi(sat)/v0)) from the Hill 
plot on the logI axis gives the IC50 value. As shown in Figure 2.4, IC50 values of lysine decrease 
with increasing pyruvate concentration up to a saturated value. Conversely, IC50 values increase 
with increasing concentration of ASA. This clearly shows that pyruvate promotes lysine binding 
while ASA hinders the binding of lysine. 
 
 
Figure 2.4  Relationship between IC50 of lysine and concentration substrates. (●) pyruvate is 
the variable substrate, concentration of ASA is 2.24 mM; (○) ASA is the variable substrate, 
concentration of pyruvate is 3.50 mM. 
2.5.5 Analysis of Dixon and Cornish-Bowden plots 
The Dixon plot (1/v versus I) and the Cornish-Bowden plot (S/v versus I) are very useful to 
distinguish between kinetic models of simple linear inhibition (38, 39), and when taken together 
they can provide distinctive patterns which can be attributed to a particular type of inhibition. 
When applying these methods to partial inhibition, a difficulty arises from the fact that the 
Cornish-Bowden plot and the Dixon plot are non-linear, but relatively straight plots can be 
obtained at concentrations of inhibitor preceding the saturation region. The effect of 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
0.12 
0.14 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 
IC
5
0
 o
f 
ly
s
in
e
, 
m
M
 
[substrate], mM 
27 
 
cooperativity must be taken into account by raising the inhibitor concentration to the power of 
the Hill coefficient (39).  
When the concentration of pyruvate was varied at constant [ASA], the plot S/v versus I
h
 
produced a series of lines converging in the second quadrant of the Cartesian coordinate system, 
and the plot 1/v versus I
h
 yielded a series of near parallel lines (at high concentrations of lysine 
these lines eventually converge in the first quadrant of the coordinate system), indicative of 
uncompetitive inhibition (Supporting information, Figure S2.7 A,B). With respect to changing 
the concentration of ASA, the Cornish-Bowden plot produced a series of lines which cross just 
below the x-axis in the third quadrant, while the Dixon plot produced lines crossing in the second 
quadrant (Supporting information, Figure S2.8 A,B). This indicates mixed inhibition, with 
binding of lysine to the F form of the enzyme prevailing over binding to the F:ASA complex. 
Note for these graphs, the lines were fit independently, rather than trying to fit the data to a 
single model, to provide an unbiased view of the data. Given the apparent complexity of the 
inhibition, a global fit of the data is needed for an independent comparison to the diagnostic 
plots. 
2.5.6 Fitting the inhibition models to observed data 
A general scheme illustrating the lysine inhibition mechanism is shown in Scheme 2.1. For 
this model, we assumed that the formation of enzyme-pyruvate and modified enzyme-ASA 
complexes are reversible and rapid steps, and the breakdown of these complexes are slow, rate-
limiting steps. Karsten (21) suggested that formation of the final product, i.e. reaction of the F 
form of the enzyme with the second substrate, ASA, is the rate-limiting step in the overall 
equilibria, therefore for this scheme k2 < k1, and our data are consistent with this. The lower part 
of the scheme illustrates partial inhibition, in which the enzyme-substrate-inhibitor complexes 
are able to convert the substrates into products at much lower rates compared to reaction rates in 
the absence of inhibitor (β' < 1, β < 1). Assuming that lysine can bind to each form of the 
enzyme, four Ki values can be determined, and based on the binding affinity of the inhibitor to a 
particular enzyme species, a decision about the mechanism of inhibition can be made. We have 
therefore used an unbiased approach and considered all applicable kinetic mechanisms of lysine 
inhibition with respect to each substrate.  
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Scheme 2.1  General scheme of DHDPS lysine inhibition. The equilibria shown in blue are not 
observed for C. jejuni DHDPS. For this general scheme, there is no limit on the values of α (and 
α′), while β (and β′) must be < 1 for inhibition. In a purely noncompetitive partial inhibition 
mechanism, α and α′ = 1, whereas in a mixed partial inhibition mechanism, α and α′ > 1.  
Since binding of lysine is a cooperative process, each rate equation was modified by raising 
the inhibitor concentration and the inhibition constants to the power of the Hill coefficient 
(Equations 2.2 – 2.4). Fitting of data was done using cooperativity coefficients as independent 
variables in the rate equations, and the resulting coefficients were compared with those found by 
the graphical method. Experimental data obtained by varying the concentration of pyruvate were 
fit using the mixed partial (hyperbolic) (Equation 2.2) and uncompetitive partial (Equation 2.3) 
models (Figure 2.5, Supporting information, Figure S2.9 - Figure S2.12). For the mixed partial 
model, the rate constant k1 (Scheme 2.1) decreases (by the factor of β') and the binding affinity of 
lysine to the E:pyr complex increases (by α'), where 0 < α' < 1, 0 < β' < 1. Two Hill coefficients, 
h and h', were introduced in to the rate equation to allow for different degrees of cooperativity of 
lysine binding to the E and E:pyr forms of the enzyme respectively. The cooperativity of 
pyruvate was equal to 1 (Figure S2.10, Figure S2.12). The uncompetitive partial model describes 
the situation when inhibitor produces its effect by binding only to the enzyme-substrate complex, 
the series of double-reciprocal plots are not parallel and the limiting plot at I = ∞ is a horizontal 
line (Figure 2.5, Supporting information, Figure S2.9, Figure S2.11). Both regression models 
describe the experimental data well (R
2
 close to one) (Supporting information, Table S2.1). For 
the mixed partial model several parameters were poorly estimated: the cooperativity of lysine 
binding to the E:pyr complex (h exceeds the number of binding sites in the tetramer), and Ki' and 
α' (have high statistical error) (Supporting information, Table S2.1). Based on the information 
obtained, including R
2
 values, distribution of residuals, and shape of secondary plots (slope and 
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intercept vs. lysine concentration - plots are not shown), preference should be given to the 
uncompetitive partial model as the model providing a good fit with fewer variables. 
The most common conclusion in the recent literature is that (S)-lysine is a partial 
noncompetitive inhibitor of DHDPS with respect to ASA (14, 16, 17), which implies that lysine 
is able to bind to both F enzyme form (pyruvate-bound) and F:ASA complex with the same 
affinity: Ki = αKi (Scheme 2.1). Assuming that the binding affinities could be different, the 
model of mixed partial inhibition (1 < α < ∞, 0 < β < 1) was considered as well. The family of 
double-reciprocal plots (1/v versus 1/[ASA] at different lysine concentrations) has a mutual point 
of convergence near the y-axis when [lysine] ≤ 0.1 mM. At high lysine concentration plots have 
a limiting slope and look more like a set of parallel lines (Figure 2.6). Taking into account that 
the apparent KM values for ASA increases at lysine concentrations less than 0.1 mM, and then 
slightly decrease at higher lysine concentrations, it can be concluded that the kinetic mechanism 
changes at saturating concentrations of lysine.  
 
Figure 2.5  Double-reciprocal plot of data obtained at a constant ASA concentration of 0.18 
mM. Concentration of lysine: (♦) 0 mM, (□) 0.04 mM, () 0.05 mM, (○) 0.06 mM, () 0.07 
mM, (△) 0.08 mM, (●) 0.10 mM. (◊) 0.20 mM, () 0.50 mM, (+) 1.00 mM. Solid lines are fit 
lines, obtained by global fitting the uncompetitive partial model to the data. Residuals are shown 
in Supporting information Figure S2.9.  
The analysis of the mechanism of lysine inhibition with respect to ASA is more complex. The 
double-reciprocal plot in Figure 2.6 again indicates two distinct conditions: at low lysine 
concentrations (≤ 0.1 mM), a family of intersecting lines is evident, as is detectable curvature of 
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the lines; at higher lysine concentrations the lines appear parallel, with no apparent curvature. 
Although there are several arguments that might explain a change in behavior of an enzyme 
saturated with an allosteric ligand, the curvature of the lines suggests that there is lysine-induced 
cooperativity of ASA under some conditions. Construction of Hill plots indicated that the 
cooperativity coefficient for ASA is a non-linear function of lysine concentration (Figure 2.7). In 
the presence of lysine, and at near-KM concentration of pyruvate, ASA binds with an average 
cooperativity coefficient n = 1.3  0.3, and this value was therefore included in Equations 2.2 
and 2.4, generating the lines of fit included in Figure 2.6 at lysine concentrations ≤ 0.1 mM. At 
saturating concentration of pyruvate the average cooperativity coefficient for ASA is close to one 
(1.1 ± 0.3). 
Regression analysis of the data indicated that while both noncompetitive partial (Figure S2.13 
and Figure S2.14) and mixed partial (Figure 2.6, Figure S2.15 and Figure S2.16) models 
approximate the data, the mixed partial model has better statistical characteristics. Analysis of 
residual plots revealed that in the case of the noncompetitive partial model (at near-KM 
concentration of pyruvate), residuals are distributed non-randomly (Figure S2.13B). This 
indicates that lysine is a mixed partial inhibitor with respect to ASA, where the inhibitor binds 
with higher affinity to the F form of the enzyme and with lower affinity to the F:ASA complex.  
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Figure 2.6  Double-reciprocal plot of data obtained at a constant pyruvate concentration of 
0.35 mM fit to the mixed partial inhibiton model (Equation 2.2, 1 < α < ∞, 0 < β < 1). Solid lines, 
Hill coefficient for ASA n = 1.3; dashed lines, n = 1. Concentration of lysine: (♦) 0 mM, (□) 0.04 
mM, () 0.05 mM, (○) 0.06 mM, () 0.07 mM, (△) 0.08 mM, (●) 0.10 mM, (◊) 0.20 mM, () 
0.50 mM, (+) 1.00 mM.   
 
 
Figure 2.7  Values of the Hill coefficient of ASA at varying concentrations of (S)-lysine and 
constant pyruvate concentrations, 0.35 mM () and 3.50 mM (○).  
The lysine inhibition results are summarized in Table 2.2. The values of dissociation 
constants, KS(pyr) and KS(ASA), are close to the KM values for these substrates in Table 2.1 (for 
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those for saturating concentration of the second substrate), which suggests that the assumptions 
which have been made about rapid and slow steps in the overall equilibria (Scheme 2.1) are 
correct. 
Table 2.2  Lysine inhibition kinetic parameters for C. jejuni DHDPS 
Kinetic model Uncompetitive partial Mixed partial 
Variable substrate Pyruvate ASA 
Fixed substrate ASA (sat.) ASA (KM) Pyruvate (sat.) Pyruvate (KM) 
hE:pyr, lysine 2.6 ± 0.1 2.9 ± 0.1   
hF, lysine   2.3 ± 0.2 2.2 ± 0.1 
hF:ASA, lysine   2.8 ± 0.2 3.2 ± 0.2 
n, ASA   1.1 ± 0.3 1.3 ± 0.3 
Ki1, mM
a 0.069  0.001 0.054  0.001   
Ki2, mM
b   0.045  0.003 0.037  0.001 
Ki3, mM
c   0.072  0.009 0.100  0.006 
KS (ASA), mM   0.12  0.01 0.073  0.003 
KS (pyr), mM 0.33  0.01 0.17  0.01   
a
 Ki1 corresponds to α'Ki' in the Scheme 2.1. 
b
Ki2 corresponds to Ki in the Scheme 2.1. 
c
Ki3 corresponds to αKi in the Scheme 2.1. 
 
2.6 Discussion 
Inhibition of DHDPS from various organisms has been studied, and the results of these 
studies have demonstrated three challenges: defining the kinetic mechanism of inhibition; 
understanding exactly how the binding of lysine to the regulatory site results in impaired 
catalysis; and the design of potent, selective inhibitors of the enzyme. The first of these 
challenges is addressed here for C. jejuni DHDPS.  
Studies on the E. coli enzyme show that the active site contains a lysine residue, Lys161, with 
which pyruvate condenses in the first chemical step of the ping-pong mechanism. The reaction 
apparently relies on a ''catalytic triad'' (34) of Thr44, Tyr133, and Tyr107' (a residue contributed 
from the other polypeptide chain of the tight dimer). Arg138 has been shown to be important for 
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ASA binding to the enzyme (40). These residues are present in C. jejuni DHDPS as Lys166, 
Thr47, Tyr137, Tyr111', and Arg142. Moreover, the structure of E. coli DHDPS with lysine 
bound in the active site shows each lysine molecule making polar contacts with seven residues of 
the protein (Ser48, Ala49, Leu51, His56, Asn80', Glu84', and Tyr106), and, as shown in Figure 
2.8, all of these residues are conserved in the allosteric site of C. jejuni DHDPS (Ser51, Ala52, 
Leu54, His59, Asn84', Glu88', and Tyr110). In short, it would be reasonable to expect these 
homologues to display very similar behaviour in catalysis and inhibition. We were therefore 
surprised to find distinct differences in the kinetic mechanism of inhibition, as demonstrated in 
independent kinetic analyses of the data: we observe that lysine is an uncompetitive partial 
inhibitor with respect to pyruvate, and a mixed partial inhibitor with respect to ASA. Kinetic 
mechanisms can vary among enzymes from different species, although some differences in our 
results may be attributed to our treatment of cooperativity in the mechanistic analysis, which was 
absent from recent treatments of the E. coli DHDPS mechanism. In arriving at our conclusions, 
we found the use of the combination of Cornish-Bowden and Dixon plots to be extremely helpful 
in differentiating the kinetic models. 
 
Figure 2.8  Overlay of the allosteric site residues of C. jejuni DHDPS (cyan), and E. coli 
DHDPS (yellow) making polar contacts with bound L-lysine (orange). Residue labels indicate E. 
coli residues making contact with one L-lysine molecule. Coordinates from RSCB PDB entries 
1YXD (E. coli) and 3LER (C. jejuni). Figure generated using PyMOL Molecular Graphics 
System, Version 1.4.1, Schrodinger, LLC.  
Binding of lysine to DHDPS has been shown to be cooperative for DHDPS from other 
sources, including E. coli (21, 24), S. meliloti (25), and V. vinifera (23). It is therefore surprising 
that although this cooperativity has been known for fifteen years, most detailed kinetic analyses 
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have not accounted for cooperativity. (During the preparation of this manuscript, a report 
describing the kinetics of inhibition of the V. vinifera DHDPS appeared, in which Hill 
coefficients were calculated and incorporated into rate equations.) In some cases perhaps, lysine 
cooperativity is small enough to be ignored, but the significant cooperativity evident with C. 
jejuni DHDPS made it clear that Hill coefficients would have to be incorporated into our 
analyses.  
As described above, the degree of cooperativity was not the same in all conditions. This is not 
surprising: the presence of pyruvate increases the affinity of the allosteric site for lysine, while 
the presence of ASA decreases the affinity of the allosteric site for lysine. In each case, the 
properties of the site have changed, albeit subtly, and therefore there is no reason for the degree 
of cooperativity to remain constant. In all conditions the value of h was between 2 and 3.2. That 
the degree of cooperativity exceeds 2.0 is significant in that it indicates that the two allosteric 
sites are not entirely independent; binding of lysine to one site affects the binding of lysine at the 
other, showing the enzyme to be functioning as a tetrameric catalyst, rather than as a dimer of 
independent dimers. It is unlikely that this site-to-site communication is due to a pronounced 
structural change, since no evidence has been observed for such changes in the very similar E. 
coli DHDPS. Dobson et al. (30) and Reboul et al. (41) have used molecular dynamics 
simulations to show the likely importance of protein dynamics to DHDPS catalysis, and the role 
that the tetrameric structure may play in maintaining optimal active site residue conformation. 
The complexity of the inhibition mechanism extends beyond the cooperativity of inhibitor 
binding. The behaviour of the enzyme at high concentrations of lysine can be differentiated from 
its behaviour at lysine concentrations below 0.1 mM. Specifically, the Lineweaver-Burk plots of 
Figure 2.6 show a different pattern, with the lines at high lysine concentrations near parallel. This 
can be understood in terms of Scheme 2.1 by considering that at high concentrations, catalysis 
passes largely through the lower pathway, i.e. the inhibitor-bound enzyme species. We also 
observe that the presence of lysine induces cooperativity in the second substrate, ASA. It may be 
that the presence of lysine restricts or alters the dynamics of the protein, which thereby alters 
several properties of catalysis, such as cooperativity of substrate binding.  
In summary, although the kinetic mechanism of inhibition is complex, there are some clear 
conclusions to be drawn from these results. Lysine is a more effective inhibitor of C. jejuni 
DHDPS than of most DHDPS from Gram-negative bacteria, and the observed kinetic mechanism 
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differs from that reported recently for DHDPS from other sources. It is evident that the inhibition 
mechanism cannot be assessed properly without accounting for the cooperativity of lysine 
binding. The value of the Hill coefficient with respect to each binding event varies somewhat, 
but in all cases h > 2, indicating that the two allosteric sites are not independent. Lysine binds 
most effectively to the F form of C. jejuni DHDPS and kinetic results suggest that lysine either 
does not bind to the E form (this equilibrium is shown in blue in Scheme 2.1) or binding of 
lysine to this form does not have an effect on inhibition kinetics. Figure 2.4 clearly shows that 
the presence of pyruvate promotes lysine binding, while ASA and lysine have an antagonistic 
relationship; the presence of ASA drives up the apparent inhibition constant of lysine, and the 
presence of lysine drives up the apparent Michaelis constant of ASA; each hinders the binding of 
the other. Finally, this is the first observation of lysine-induced cooperativity of ASA. As 
observed previously for other DHDPS enzymes, there is no cooperativity in the absence of 
lysine, but the curvature of the lines in Figure 2.6 clearly demonstrates the low but significant 
cooperativity of the second substrate. The specifics of the signal transduction between active site 
and allosteric site, and between antipodal allosteric sites, remain unclear, but will be aided by 
biophysical studies of this protein including high-resolution crystallographic studies. 
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2.9 Supporting Information 
 
Figure S2.1  Double-reciprocal plots of the DHDPS-catalyzed reaction. Solid lines are the 
global fit of the data to Equation 2.1) (R
2
 is 0.985703). (A) Concentration of pyruvate is varied: 
() 0.2 mM, (▲) 0.5 mM, (Ж) 1.0 mM, (□) 1.5 mM, (♦) 2.0 mM, () 3.0 mM. (B) Concentration 
of ASA is varied: (●) 0.09 mM, (△) 0.32 mM, (■) 0.68 mM, (◊) 0.91 mM, (+) 1.37 mM, (○) 2.28 
mM.  
 
 
Figure S2.2  Residuals for plots in Figure S2.1.
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Figure S2.3  (A) Hill plots at 2.24 mM ASA and varied concentrations of pyruvate: (♦) 0.15 
mM, (□) 0.20 mM, () 0.35 mM, (○) 0.50 mM, (◊) 1.00 mM, (●) 3.50 mM. Solid lines were 
obtained by linear regression. (B) Values of the Hill coefficient of lysine at varying 
concentration of pyruvate. 
 
     
Figure S2.4  (A) Hill plots at 3.50 mM pyruvate and varied concentration of ASA: (♦) 2.24 
mM, (□) 0.54 mM, () 0.31 mM, (○) 0.18 mM, (◊) 0.16 mM, (●) 0.09 mM. Solid lines were 
obtained by linear regression. (B) Values of the Hill coefficient of lysine at varying 
concentrations of ASA. 
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Figure S2.5  (A) Hill plots at 0.18 mM ASA and varied concentrations of pyruvate: (♦) 0.12 
mM, (□) 0.14 mM, () 0.19 mM, (○) 0.30 mM, (◊) 0.50 mM, (●) 1.00 mM, () 3.50 mM. Solid 
lines were obtained by linear regression. (B) Values of the Hill coefficient of lysine at varying 
concentrations pyruvate. 
 
   
Figure S2.6  (A) Hill plots at 0.35 mM pyruvate and varied concentrations of ASA: (♦) 0.06 
mM, (□) 0.07 mM, () 0.11 mM, (○) 0.15 mM, (◊) 0.29 mM, (●) 2.00 mM. Solid lines were 
obtained by linear regression. (B) Values of the Hill coefficient of lysine at varying 
concentrations of ASA. 
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Figure S2.7  Cornish-Bowden plot (A) and Dixon plot (B) of the inhibition of the DHDPS-
catalyzed reaction by lysine with respect to pyruvate. Concentration of pyruvate is 0.15 (◊), 0.20 
(●), 0.35 (□), 0.50 (ж), 1.00 (), 3.50 () mM; concentration of ASA 2.24 mM. Solid lines were 
obtained by linear regression. 
 
  
Figure S2.8  Cornish-Bowden plot (A) and Dixon plot (B) of the inhibition of the DHDPS-
catalyzed reaction by lysine with respect to ASA. Concentration of ASA is 0.09 (), 0.16 (◊), 
0.18 (●), 0.31 (○), 0.54 (), 2.24 () mM; concentration of pyruvate is 3.50 mM. Solid lines 
were obtained by linear regression. 
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Figure S2.9  Residuals for plot in Figure 2.5. 
 
    
Figure S2.10  (A) Double-reciprocal plots of data obtained at a constant ASA concentration of 
0.18 mM. Concentration of lysine: (♦) 0 mM, (□) 0.04 mM, () 0.05 mM, (○) 0.06 mM, () 
0.07 mM, (△) 0.08 mM, (●) 0.10 mM. (◊) 0.20 mM, () 0.50 mM, (+) 1.00 mM. Solid lines are 
fit lines, obtained by global fitting the mixed partial model to the data (0 < α' < 1, 0 < β' < 1). (B) 
Residuals for Figure S2.10A. 
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Figure S2.11  (A) Double-reciprocal plots of data obtained at a constant ASA concentration of 
2.24 mM. Concentration of lysine: (♦) 0 mM, (□) 0.02 mM, () 0.04 mM, (○) 0.05 mM, () 
0.06 mM, (△) 0.07 mM, (●) 0.10 mM. (◊) 0.20 mM, (+) 2.00 mM. Solid lines are fit lines, 
obtained by global fitting the uncompetitive partial model to the data. (B) Residuals for Figure 
S2.11A.  
             
Figure S2.12  (A) Double-reciprocal plot of data obtained at a constant ASA concentration of 
2.24 mM. Concentration of lysine: (♦) 0 mM, (□) 0.02 mM, () 0.04 mM, (○) 0.05 mM, () 
0.06 mM, (△) 0.07 mM, (●) 0.10 mM. (◊) 0.20 mM, (+) 2.00 mM. Solid lines are fit lines, 
obtained by global fitting the mixed partial model to the data (0 < α' < 1, 0 < β' < 1). (B) 
Residuals for Figure S2.12A. 
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Table S2.1 Comparison of kinetic constants calculated by global fitting using alternative 
kinetic models, showing poorly estimated parameters and poorer fits for the mixed partial model 
with respect to pyruvate and the noncompetitive partial model with respect to ASA. 
 
With respect to pyruvate With respect to ASA 
Parameters, 
models 
Mixed partial 
Uncompetitive 
partial 
Mixed partial 
Noncompetitive 
partial 
Concentration 
of the second 
substrate 
KM saturating KM saturating KM saturating KM saturating 
Vmax, μmol∙mg
-
1∙s-1 
1.08 ± 
0.02 
2.03 ± 
0.03 
1.08 ± 
0.02 
2.03 ± 
0.03 
1.01 ± 
0.01 
1.89 ± 
0.04 
1.22 ± 
0.04 
2.02 ± 
0.05 
KS, mM 
0.17 ± 
0.01 
0.33 ± 
0.01 
0.17 ± 
0.01 
0.33 ± 
0.01 
0.073 ± 
0.003 
0.12 ± 
0.01 
0.15 ± 
0.01 
0.16 ± 
0.01 
α     2.7 ± 0.1 1.6 ± 0.2 1 1 
β     
0.14 ± 
0.01 
0.08 ± 
0.02 
0.15 ± 
0.02 
0.086 ± 
0.018 
α' 
0.25 ± 
0.21* 
0.22 ± 
0.28* 
      
β' 
0.10 ± 
0.07* 
0.067 ± 
0.011 
0.097 ± 
0.004 
0.064 ± 
0.007 
    
n (ASA)     1.0, 1.3
1
 1.0, 1.1
3
 1.0, 1.3
1
  1.0, 1.1
3
 
hE (lysine) 
4.2 ± 
2.3* 
3.3 ± 2.1*       
hE:pyr (lysine) 2.9 ± 0.1 2.6 ± 0.1 2.9 ± 0.1 2.6 ± 0.1     
hF (lysine)     2.2 ± 0.1
2
 2.3 ± 0.2
4
 2.5 ± 0.3 2.6 ± 0.2 
hF:ASA (lysine)     3.2 ± 0.2
2
 2.8 ± 0.2
4
 2.5 ± 0.3 2.6 ± 0.2 
Ki' 
0.22 ± 
0.19* 
0.31 ± 
0.39* 
      
α'Ki' 
0.055 ± 
0.066* 
0.068 ± 
0.122* 
0.054 ± 
0.007 
0.069 ± 
0.001 
    
Ki     
0.037 ± 
0.001 
0.045 ± 
0.003 
0.071 ± 
0.003 
0.062 ± 
0.002 
αKi     
0.100 ± 
0.006 
0.072 ± 
0.009 
0.071 ± 
0.003 
0.062 ± 
0.002 
R
2
 0.993299 0.993712 0.993341 0.993801 0.995676 0.987739 0.968191 0.981916 
* Poorly estimated parameters 
1
 Average Hill coefficients for ASA were used: n = 1.0 (in the absence of lysine and in the range of lysine 
concentrations from 0.2 to 1.0 mM), n = 1.3 (in the range of lysine concentrations from 0.04 to 0.1 mM), based on 
the results shown in Figure 2.7.  
2
 Hill coefficients for lysine were found by global fitting of the model to data, in the range of lysine concentration 
from 0.2 to 1.0 mM of lysine the fit was produced by reducing Hill coefficients from 2.2 to 1.4 (hF) and from 3.2 to 
1.95 (hF:ASA). 
3
 Average Hill coefficients for ASA were used: n = 1.0 (in the absence of lysine and in the range of lysine 
concentrations from 0.2 to 2.0 mM), n = 1.1 (in the range of lysine concentrations from 0.02 to 0.2 mM), based on 
the results shown in Figure 2.7.  
4
 Hill coefficients for lysine were found by global fitting of the model to data, in the range of lysine concentration 
from 0.2 to 2.0 mM the fit was produced by reducing Hill coefficients from 1.9 to 1.4 (hF) and from 2.5 to 1.7 
(hF:ASA).
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Figure S2.13  Fit of the data obtained at a constant pyruvate concentration of 0.35 mM to the 
noncompetitive partial model. (A) Double-reciprocal plot of data obtained at concentration of 
lysine: (♦) 0 mM, (□) 0.04 mM, () 0.05 mM, (○) 0.06 mM, () 0.07 mM, (△) 0.08 mM, (●) 
0.10 mM. Solid lines are fit lines, obtained by global fitting of the data to Equation 2.4. (B) 
Residuals for Figure S2.13A. 
 
     
Figure S2.14  (A) Double-reciprocal plot of data obtained at a constant pyruvate concentration 
of 3.50 mM. Concentration of lysine: (♦) 0 mM, (□) 0.02 mM, () 0.04 mM, (○) 0.05 mM, () 
0.06 mM, (△) 0.07 mM, (●) 0.10 mM, (‒) 0.20 mM, (+) 2.00 mM. Solid lines are fit lines, 
obtained by global fitting the noncompetitive partial model to the data. (B) Residuals for Figure 
S2.14A.  
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Figure S2.15   (A) Double-reciprocal plots. Data obtained at constant pyruvate concentration 
3.50 mM. Concentration of lysine: (♦) 0 mM, (□) 0.02 mM, () 0.04 mM, (○) 0.05 mM, () 
0.06 mM, (△) 0.07 mM, (●) 0.10 mM, (‒) 0.20 mM, (+) 2.00 mM. Solid lines are fit lines, 
obtained by global fitting the mixed partial model (1 < α < ∞, 0 < β < 1) to the data. (B) 
Residuals for Figure S2.15A. 
 
 
Figure S2.16  Residuals for plot in Figure 2.6. 
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Figure S2.17  (A) 12% SDS-PAGE of C. jejuni DHDPS; (B) 15% SDS-PAGE of C. jejuni 
DHDPR. Left lane on A and B is M3913 Sigma Marker
TM 
protein ladder. 
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CHAPTER 3.   R,R-BISLYSINE: A POTENT, NONCOMPETITIVE SLOW-
BINDING INHIBITOR OF DIHYDRODIPICOLINATE SYNTHASE FROM 
CAMPYLOBACTER JEJUNI 
3.1 Introduction 
Dihydrodipicolinate synthase (DHDPS, E.C. 4.2.1.52) is an enzyme catalyzing the 
condensation of pyruvate and (S)-aspartate-β-semialdehyde (ASA) into an unstable heterocyclic 
product (4S)-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate (HTPA), which spontaneously 
dehydrates into 2,3-dihydrodipicolinate (DHDP) (1, 2). DHDPS catalyzes the first committed 
step in L-lysine and meso-diaminopimelate biosynthesis in bacteria, plants and some fungi (3-5). 
L-Lysine and meso-diaminopimelate are essential components of bacterial cell walls (6). DHDPS 
is encoded by a dapA gene (7), and studies revealed that mutant auxotrophs for diaminopimelate 
undergo lysis in the absence of diaminopimelate in the medium (8). E. coli AT997 (a dapA 
mutant strain) can be maintained on nutrient medium only if the medium is supplemented with 
diaminopimelate (7, 9). As a result of studying the B. subtilis genome, dapA was classified as 
“essential” (10). Genome analysis and mapping by in vitro transposition in H. influenza 
putatively identified dapA as an “essential” gene (11). These results show that DHDPS is a 
potential target for drug development (12). However, Schnell et al. has shown that Pseudomonas 
aeruginosa mutants with dapA deleted are viable, implying that dapA is not an optimal target for 
drug development against that bacteria (13). 
The activity of DHDPS is regulated by L-lysine, which binds at an allosteric site of the 
enzyme (2). DHDPS from plants and Gram-negative bacteria are more sensitive to lysine 
inhibition, showing micromolar or millimolar IC50 values (14-18). DHDPS from Gram-positive 
bacteria is weakly inhibited or insensitive to L-lysine (19-21). 
Potent inhibitors of DHDPS have not yet been reported, despite many years effort. Various 
research groups focus mostly inhibitor design on the active site of the enzyme, and a number of 
millimolar range inhibitors have been presented in the literature. Among them are analogs of 
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substrates (pyruvate and ASA) (12, 22, 23), analogs of product (HTPA or DHDP) (3, 12, 23-27), 
and mimics of enzyme-bound condensation products of ASA and pyruvate (28-31).  
Until now there were no attempts to design an allosteric inhibitor of DHDPS. Based on the 
results of isothermal titration calorimetry, Phenix and Palmer (32) suggested that an effective 
strategy of inhibitor design would be mimicking a pair of bound lysine molecules. The distance 
between the α-carbons of two bound L-lysines, based on the crystal structure of E. coli DHDPS 
PDB ID 1YXD is 4.1 Å. This distance appeared to be able to accommodate a two-carbon bridge 
connecting to the lysine molecules (Figure 3.1). The resulting molecule ''bislysine'' would have 
stereocenters designated R- (due to the change in substituent priorities) to mimic (S)-lysine. This 
bis-inhibitor analog we predicted would be more effective than lysine itself, because the entropic 
barrier to binding of the second inhibitor molecule would be eliminated.  
 
 
Figure 3.1  Crystal structure of two L-lysines bound at the allosteric site of E. coli DHDPS 
(PDB ID 1YXD).   
Here we report the synthesis of R,R-bislysine, and its potent inhibition of DHDPS from 
Campylobacter jejuni. We have shown that R,R-bislysine is a close mimic and superior inhibitor 
to lysine. 
The inhibitory activity of L-thialysine (S-aminoethyl-L-cysteine), a known weak 
noncompetitive inhibitor of E. coli DHDPS, and α-methyl-DL-lysine, a close mimic of L-lysine 
with a methyl substituent at the α carbon was also tested. This study will explore how tolerant 
the allosteric site of DHDPS is to different functionalities.  
51 
 
3.2 Experimental 
3.2.1 General experimental procedures 
Chemicals were purchased from Sigma-Aldrich Canada, Ltd (Oakville, ON) or Alfa Aesar 
(Ward Hill, MA). Reactions that required anhydrous conditions were conducted under a dry 
nitrogen atmosphere using oven-dried glassware. Dry DCM and THF were obtained using a MB-
Solvent Purification System (University of Saskatchewan); diisopropylamine was freshly 
distilled from CaH2. HMPA was distilled under vacuum from CaH2 and stored over activated 4Å 
molecular sieves. Flash chromatography was performed using Merck silica gel 60 (230-400 
mesh). Thin layer chromatography was conducted using silica gel 60 F254 aluminum plates; 
visualisation of spots was performed under UV lamp (254 nm) and by charring after treatment 
with cerium phosphomolybdate. NMR spectra were recorded on a Bruker 500 MHz 
spectrometer. Mass spectra were acquired on a Qstar XL MS/MS System Applied 
Biosystems/MDS Sciex and VG 70-VSE mass spectrometer (VG Analytical Inc. Ltd.) at the 
Saskatchewan Structural Sciences Centre. 
3.2.2 α-Methyl-DL-lysine synthesis  
Methyl (2S)-2,6-diaminohexanoate (1) 
 
A round bottom flask was charged with methanol (10 ml) under a nitrogen atmosphere and 
cooled on ice. Acetyl chloride (1.17 ml, 16.4 mmol) was added dropwise with stirring over a 
period of 10 min. The solution was stirred for 5 min, then solid (S)-lysine (monohydrochloride) 
(1.0 g, 5.48 mmol) was added in one portion to the flask and the resulting suspension was slowly 
heated to reflux. After 2 h of refluxing (at 65 °C) the mixture was cooled down and solvent was 
evaporated in vacuo to afford a white crystalline product 1 as a dihydrochloride salt in 98% yield 
(1.25 g, 5.36 mmol). The product was used for the next step without further purification. 
1
H 
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NMR (500 MHz, D2O): δ 4.14 (t, J = 6.4 Hz, 1H), 3.82 (s, 3H), 2.98 (t, J = 7.6 Hz, 2H), 2.05 – 
1.87 (m, 2H), 1.68 (p, J = 7.6 Hz, 2H), 1.57 – 1.38 (m, 2H).  
Methyl (2S)-2,6-bis{[(tert-butoxy)carbonyl]amino}hexanoate (2) 
 
The starting material 1 (1.25 g, 5.37 mmol) was added to dry THF (16 ml) in a round-bottom 
flask under nitrogen, followed by triethylamine (2.99 ml, 21.46 mmol), and the resulting 
suspension was cooled on ice. A solution of di-tert-butyl dicarbonate (2.34 g, 10.73 mmol) in dry 
THF (16 ml) was added slowly over period of 1 h to the stirring suspension. The ice bath was 
removed and the mixture was left stirring for 14 h at rt and then warmed at 50 °C for 3 h. The 
solvent was removed under reduced pressure and the residue was partitioned between diethyl 
ether and a saturated solution of sodium bicarbonate (20 ml each). The aqueous layer was 
additionally extracted by diethyl ether (30 ml). The combined ethereal layer was washed with 
brine, dried with anhydrous sodium sulfate, and concentrated in vacuo. Purification by FCC 
(25% EtOAc:hexane) afforded a white solid 2 in quantitative yield (1.92 g, 5.33 mmol). 
1
H NMR 
(500 MHz, CDCl3): δ 5.08 (d, J = 6.9 Hz, 1H), 4.56 (bs, 1H), 4.28 (q, J = 7.2, Hz, 1H), 3.73 (s, 
3H), 3.11 (dd, J = 12.3 Hz, J = 6.3 Hz, 2H), 1.85 – 1.75 (m, 1H), 1.69 – 1.59 (m, 1H), 1.55 – 
1.45 (m, 2H), 1.44 (s, 18H), 1.40 – 1.30 (m, 2H).  
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Methyl (±)-2,6-bis{[(tert-butoxy)carbonyl]amino}-2-methylhexanoate (3) 
 
A dry round bottom flask was charged with dry THF (7 ml) under nitrogen. Freshly distilled 
diisopropylamine (0.29 ml, 2.08 mmol) was added via syringe and the flask was cooled to -78 °C 
in a dry ice/acetone bath. A freshly titrated solution of n-butyllithium (0.93 ml, 1.89 mmol) in 
hexanes was added dropwise over a period of 10 min, and the reaction flask was then placed on 
ice for 30 min to form LDA. The solution was cooled down again to -78 °C. Compound 2 (0.200 
g, 0.556 mmol) was dissolved in a minimum amount of dry THF (1 ml) and the resulting 
solution was added slowly via syringe to the stirring solution of LDA over a period of 10 min 
and the reaction was left to stir for 30 min. Finally, neat methyl iodide (0.19 ml, 3.06 mmol) was 
added. After 1 h, the reaction was quenched by a saturated solution of NH4Cl, and the mixture 
was partitioned between ethyl acetate (20 ml) and saturated NH4Cl (20 ml). The organic phase 
was washed with saturated NaHCO3 (25 ml) and then brine (25 ml). The organic solvent was 
evaporated under reduced pressure affording a yellow oily residue. FCC (20% EtOAc/hexane) 
afforded the title compound 3 (as a racemic mixture) in a 54% yield as colorless oil (0.112 g, 
0.300 mmol).
1
H NMR (500 MHz, CDCl3): δ 5.32 (bs, 1H), 4.54 (bs, 1H), 3.72 (s, 3H), 3.09 (d, J 
= 5.2 Hz, 2H), 2.03 (bs, 1H), 1.77 (td, J = 13.0 Hz, J = 4.6, 1H), 1.50 (s, 3H), 1.48 – 1.42 (m, 
1H), 1.42 (s, 9H), 1.44 (s, 9H), 1.34 – 1.22 (m, 1H), 1.18 – 1.06 (m, 1H). 13C NMR (125 MHz, 
CDCl3): δ 175.1, 156.2, 154.5, 79.5, 79.2, 59.6, 52.7, 40.1, 36.6, 30.0, 28.54, 28.48, 23.6, 21.5. 
HRMS m/z calcd. for C18H34N2O6Na [M + Na]
+
 397.2309, found 397.2305 (ESI). 
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(±)-2,6-diamino-2-methylhexanoic acid (α-methyl-DL-lysine) (4) 
 
A 1:1 mixture of 12M HCl and MeOH (6 ml) was added to the racemic mixture 3 (0.056 g, 
0.149 mmol) and stirred at rt for 1h. The solvent was evaporated in vacuo and 6M HCl (aqueous) 
(5 ml) was added to the remaining residue. The resulting solution was heated to reflux. After 8 h 
the solvent was evaporated under reduced pressure affording racemic mixture 4 as a yellow solid 
in 91% yield (0.032 g, 0.136 mmol) in a form of dihydrochloride salt. 
1
H NMR (500 MHz, D2O): 
δ 2.98 (t, J = 7.6 Hz, 2H), 2.00 – 1.92 (m, 1H), 1.92 – 1.83 (m, 1H), 1.68 (p, J = 7.6 Hz, 2H), 
1.56 (s, 3H), 1.52 – 1.49 (m, 1H), 1.38 – 1.28 (m, 1H). 13C NMR (125 MHz, D2O): δ 174.4, 60.2, 
39.0, 36.2, 26.6, 21.7, 20.2. HRMS m/z calcd. for C7H17N2O2 [M + H]
+
 161.1284, found 
161.1279 (ESI). 
 
3.2.3  (±)-Bislysine synthesis 
Dimethyl 2,5-dibromohexanedioate (5) 
 
The procedure of obtaining meso-2,5-dibromohexanedioate from hexanedioyl dichloride (33) 
was reported previously (34). Neat thionyl chloride (40.0 g, 342 mmol) was added to 
hexanedioic (adipic) acid (20.0 g, 137 mmol) and refluxed under an inert atmosphere at 80 °C for 
3 h. Excess thionyl chloride was removed under reduced pressure. To the remaining hexanedioyl 
dichloride, neat bromine (54.7 g, 342 mmol) was added and the mixture was heated to 80 °C 
using similar reaction setup as described by Watson and O’Neill (34). Additionally, a 500 Watt 
halogen lamp was placed approximately 10 cm from the reaction flask. The bromination reaction 
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was monitored by NMR and an additional 0.25 equivalents of bromine were added until the 
reaction was complete. After the reaction was completed (6 – 7 h) the excess bromine was 
removed by purging with a stream of nitrogen gas into the flask (34), and the crude product was 
added dropwise (via a syringe) to cold methanol (140 ml) on ice. The resulting suspension was 
left stirring for 14 h at room temperature. The product was then filtered. The product was 
obtained in 87% yield (39.6 g, 119 mmol). 
1
H NMR (500 MHz, CDCl3): δ 4.26 (t, J = 4.4 Hz, 
2H), 3.80 (s, 3H), 2.35 – 2.26 (m, 2H), 2.12 – 2.02 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 
165.6, 54.4, 45.9, 34.6. HRMS m/z calcd. for C8H16N1Br2O4 [M + NH4]
+
 349.9426, found 
349.9419 (CI). 
Dimethyl 2,5-bis(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)hexanedioate (6) 
 
The mixture of stereoisomers 6 was obtained using a reported method (35). To a stirring 
solution of 5 (3.80 g, 11.4 mmol) in dry DMF (20 ml), potassium phthalimide (10.5 g, 56.7 
mmol) was added in one portion. The mixture was heated to 90 °C, and the reaction continued 
for 2 h. Then the cooled reaction mixture was diluted with chloroform (25 ml) and the resulting 
solution was poured into water (100 ml). The organic layer was separated and the aqueous layer 
was extracted twice with chloroform. The chloroform layers were combined and the organic 
solvent was evaporated under reduced pressure to the point of crystallisation, followed by 
addition of diethyl ether (30 ml) to promote rapid crystallization. The product was washed with 
diethyl ether and dried in vacuo to obtain 6 as an off-white solid in 90% yield (4.77 g, 10.3 
mmol), which was used for the next step. 
1
H NMR (500 MHz, CDCl3): δ 7.90 – 7.85 (m, 4H), 
7.89 – 7.74 (m, 4H), 4.81 (t, J = 5.0, Hz, 2H,), 3.68 (s, 6H), 2.39 – 2.29 (m, 2H), 2.29 – 2.19 (m, 
2H). 
13
C NMR (125 MHz, CDCl3): δ 165.2, 163.6, 131.8, 129.5, 121.7, 54.0, 53.1, 28.6. HRMS 
m/z calcd. for C24H20N2O8 [M
•+
] 464.1220, found 464.1230 (EI). 
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2,5-Diaminohexanedioic acid (7) 
 
The reaction had been described by Sheehan (35), and following the reported procedure, to 
the mixture of stereoisomers 6 (21.9 g, 47.2 mmol), a 1:1 mixture of 48% HBr (in water) and 
glacial acetic acid (100 ml) was added, and the mixture was refluxed at 115 °C while stirring. 
After hydrolysis was completed (the reaction mixture becomes clear in approximately 14 days), 
the cooled reaction mixture was filtered to remove phthalic acid and the filtrate was evaporated 
in vacuo. The residue was dissolved in water (40 ml), filtered and the filtrate was neutralized 
with concentrated solution of ammonia. The obtained white precipitate was filtered and dried. 
The product mixture of stereoisomers 7 (7.9 g, 45.3 mmol) was obtained in 96% yield. 
1
H NMR 
(500 MHz, CD3OD): δ 4.09 (d, J = 2.2 Hz, 2H), 2.30 – 2.00 (m, 4H). 
13
C NMR (125 MHz, 
CD3OD): δ 165.6, 53.1, 28.5. HRMS m/z calcd. for C6H11N2O4 [M – H]
–
 175.0724, found 
175.0729 (ESI). 
Dimethyl 2,5-diaminohexanedioate dihydrochloride (8) 
 
Esterification was carried out using a procedure described previously (36). A round bottom 
flask was charged with methanol (3.0 ml) and cooled on ice under nitrogen. Acetyl chloride 
(0.189 ml, 2.73 mmol) was added dropwise over a period of 10 min. The solution was stirred for 
5 min, then solid compound 7 (2,5-diaminoadipic acid) (80 mg, 0.455 mmol) was added in one 
portion to the flask and the resulting suspension was slowly heated to reflux. After 2 h of 
refluxing (at 65 °C) the mixture was cooled down and solvent was evaporated in vacuo to afford 
a white crystalline product 8 as a dihydrochloride salt in quantitative yield (126 mg, 0.455 
mmol). The product was used for the next step without further purification. 
1
H NMR (500 MHz, 
CD3OD): δ 4.18 – 4.15 (m, 2H), 3.87 (s, 6H), 2.25 – 1.95 (m, 4H). 
13
C NMR (125 MHz, 
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CD3OD): δ 165.6, 53.1, 28.5. HRMS m/z calcd. for C8H16N2O4 [M
•+
] 204.1110, found 204.1100 
(EI). 
Dimethyl 2,5-bis([(tert-butoxy)carbonyl]amino)hexanedioate (9) 
 
The protection of amino groups was carried out using a procedure reported by Dondoni (36). 
The starting material 8 (2.08 g, 7.51 mmol) was added to THF (30 ml) in a round-bottom flask 
under nitrogen, followed by triethylamine (4.19 ml, 30.0 mmol), and the resulting suspension 
was cooled on ice. A solution of di-tert-butyl dicarbonate (4.91 g, 22.5 mmol) in THF (30 ml) 
was added slowly over period of 1 h to the stirring suspension. The ice bath was removed and the 
mixture was left stirring for 14 h at rt and then warmed at 50 °C for 3 h. The solvent was 
removed under reduced pressure and the residue was partitioned between diethyl ether and a 
saturated solution of sodium bicarbonate (40 ml each). The aqueous layer was additionally 
extracted by diethyl ether (30 ml). The combined ethereal layer was washed with brine, dried 
with anhydrous sodium sulfate, and concentrated in vacuo. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded a white crystalline solid 9 in 72% yield (2.18 g, 
5.41 mmol). 
1
H NMR (500 MHz, CDCl3): δ 5.15 – 5.02 (m, 2H), 4.29 (s, 2H), 3.73 (s, 6H), 1.95 
– 1.77 (m, 2H), 1.75 – 1.60 (m, 2H), 1.43 (s, 18H). 13C NMR (125 MHz, CDCl3): δ 168.6, 152.0, 
80.1, 54.4, 53.6, 31.0, 30.6. HRMS m/z calcd. for C18H32N2O8Na [M + Na]
+
 427.2050, found 
427.2062 (ESI). 
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Mixture of dimethyl (2R, 5R)-2,5-bis([(tert-butoxy)carbonyl]amino)-2,5-bis(4-
chlorobutyl)hexanedioate and dimethyl (2S, 5S)-2,5-bis([(tert-butoxy)carbonyl]amino)-2,5-
bis(4-chlorobutyl)hexanedioate (10a); dimethyl (2R, 5S)-2,5-bis([(tert-
butoxy)carbonyl]amino)-2,5-bis(4-chlorobutyl)hexanedioate (10b) 
 
A dry round bottom flask was charged with a 10% solution of HMPA in dry THF (10 ml) 
under nitrogen. Freshly distilled diisopropylamine (0.59 ml, 4.18 mmol) was added via syringe 
and the flask was cooled to -78 °C in a dry ice/acetone bath. A freshly titrated solution of n-
butyllithium (1.61 ml, 3.80 mmol) in hexanes was added dropwise over a period of 10 min, and 
the reaction flask was then placed on ice for 30 min to form LDA. The solution was cooled down 
again to -78 °C. The mixture 9 (0.349 g, 0.863 mmol) was dissolved in a minimum amount of 
dry THF (approximately 2 ml) and the resulting solution was added slowly via syringe to the 
stirring solution of LDA over a period of 20 min and the reaction was left to stir for 30 min. An 
additional portion of n-butyllithium (0.73 ml, 1.73 mmol) was added slowly, and the reaction 
was stirred for another 15 min. Finally, neat 1-bromo-4-chlorobutane (0.30 ml, 2.59 mmol) was 
added and the reaction monitored by TLC. After 45 min, the reaction was quenched by a 
saturated solution of NH4Cl, and the mixture was partitioned between ethyl acetate (25 ml) and 
saturated NH4Cl (25 ml). The organic phase was washed with saturated NaHCO3 (25 ml) and 
then brine (25 ml). The organic solvent was evaporated under reduced pressure affording a 
yellow oily residue. Flash column chromatography (15% EtOAc/hexane) afforded the title 
compounds 10a and 10b in a 12% yield as white crystalline solids (50 mg, 0.085 mmol and 12 
mg, 0.021 mmol respectively). The meso compound 10b eluted first followed by the racemic 
mixture 10a. One third of the starting material was recovered. Monoalkylated side products as 
well as some elimination side products were also observed. The meso compound 10b and the 
racemic mixture 10a were distinguished later, after the inhibition tests with DHDPS. 10a: 
1
H 
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NMR (500 MHz, CDCl3): δ 5.41 (bs, 2H), 3.74 (s, 6H), 3.49 (t, J = 6.6 Hz, 4H), 2.30 – 2.12 (m, 
4H), 1.72 (t, J = 6.9 Hz, 4H), 1.78 – 1.68 (m, 2H), 1.49 (t, J = 11.7 Hz, 2H), 1.42 (s, 18H), 1.42 – 
1.32 (m, 2H), 1.22 – 1.10 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 169.8, 150.5, 79.4, 63.7, 
53.9, 46.1, 36.4, 34.3, 32.0, 30.7, 23.8. HRMS m/z calcd. for C26H46N2O8Cl2Na  [M + Na]
+
 
607.2523, found 607.2503 (ESI). 10b: 
1
H NMR (500 MHz, CDCl3): δ 5.62 (bs, 2H), 3.74 (s, 
6H), 3.49 (dt, J = 6.6 Hz, J = 1.3 Hz, 4H), 2.35 – 2.25 (m, 2H), 2.04 (d, J = 7.6 Hz, 2H), 1.75 – 
1.64 (m, 8H), 1.43 (s, 18H), 1.42 – 1.35 (m, 2H), 1.17 – 1.05 (m, 2H). 13C NMR (125 MHz, 
CDCl3): δ 169.7, 150.2, 79.2, 64.1, 54.1, 46.1, 36.6, 34.3, 32.5, 30.7, 23.9. HRMS m/z calcd. for 
C26H46N2O8Cl2Na [M + Na]
+
 607.2523, found 607.2525 (ESI). 
Mixture of dimethyl (2R, 5R)-2,5-bis([(tert-butoxy)carbonyl]amino)-2,5-bis[4-(1,3-dioxo-
2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate and dimethyl (2S, 5S)-2,5-bis([(tert-
butoxy)carbonyl]amino)-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-
yl)butyl]hexanedioate (11) 
 
To a solution of 10a (61.9 mg, 0.106 mmol) in dry DMF (4 ml), solid potassium phthalimide 
(98 mg, 0.522 mmol) was added in one portion, followed by finely ground potassium iodide 
(43.9 mg, 0.265 mmol). The mixture was heated to 90 °C under nitrogen. After 2 h, DMF was 
evaporated under reduced pressure, and the residue was partitioned between chloroform and 
water (5 ml of each), and the aqueous layer was extracted twice with chloroform (2 ml). The 
organic layers were combined and the solvent evaporated in vacuo. Flash column 
chromatography (40% EtOAc/hexane) gave the title mixture 11 in 50% yield (43 mg, 0.053 
mmol) as colourless oil. 
1
H NMR (500 MHz, CDCl3): δ 7.82 (dd, J = 5.4 Hz, J = 3.2 Hz, 4H), 
7.69 (dd, J = 5.4 Hz, J = 3.2 Hz, 4H), 5.40 (bs, 2H), 3.71 (s, 6H), 3.61(dt, J = 7.3 Hz, J = 2.8 Hz, 
4H), 2.18 (bs, 4H), 1.76 (dt, J = 13.2 Hz, J = 4.4 Hz, 2H), 1.65 – 1.56 (m, 4H), 1.50 (t, J = 11.7 
Hz, 2H), 1.38 (s, 18H), 1.30 – 1.20 (m, 2H), 1.05 (bs, 2H). 13C NMR (125 MHz, CDCl3): δ 
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174.1, 168.4, 153.9, 134.0, 132.2, 123.3, 79.4, 62.9, 52.8, 37.7, 35.0, 29.7, 28.4, 21.3. HRMS m/z 
calcd. for C42H54N4O12Na  [M + Na]
+
 829.3630, found 829.3638 (ESI). 
Mixture of (2R, 5R)-2,5-diamino-2,5-bis(4-aminobutyl)hexanedioate tetrabromide and (2S, 
5S)-2,5-diamino-2,5-bis(4-aminobutyl)hexanedioate tetrabromide (12) 
 
A 1:1 mixture of 48% HBr (in water) and glacial acetic acid (4 ml) was added to the racemic 
mixture 11 (33.6 mg, 0.0416 mmol) and heated to 115 °C. After 3 days the solvent was 
evaporated under reduced pressure and the brown residue was dissolved in distilled water (1.5 
ml). Cation exchange resin, AG 50W-X2 (Bio-Rad) (acidic form), was prepared according to the 
manufacture’s procedure and packed in a glass Pasteur pipette (6 cm high). The sample dissolved 
in water was slowly applied onto the column. The column was washed first with water (10 ml), 
then with 1M HBr (10 ml), and eluted with 2M HBr (15 ml). Fractions eluting with 2M HBr 
were evaporated under reduced pressure and the product 12 was obtained as a colorless solid in 
88% yield (23.5 mg, 0.0366 mmol). 
1
H NMR (500 MHz, D2O): δ 3.05 (t, J = 7.6 Hz, 4H), 2.13 – 
1.99 (m, 4H), 1.99 – 1.85 (m, 4H), 1.75 (p, J = 7.6 Hz, 4H), 1.61 – 1.59 (m, 2H), 1.43 – 1.31 (m, 
2H). 
13
C NMR (125 MHz, D2O): δ 170.8, 65.9, 42.6, 38.4, 33.9, 30.7, 24.4. HRMS m/z calcd. for 
C14H31N4O4 [M + H]
+
 319.2339, found 319.2352 (ESI). 
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Mixture of dimethyl (2R, 5R)-2,5-diamino-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-
yl)butyl]hexanedioate and dimethyl (2S, 5S)-2,5-diamino-2,5-bis[4-(1,3-dioxo-2,3-dihydro-
1H-isoindol-2-yl)butyl]hexanedioate (13) 
 
To the mixture 11 (23.4 mg, 0.0290 mmol) in dichloromethane (2.5 ml), TFA (2.5 ml) was 
added slowly and the mixture was stirred at rt for 1h. The solvent was evaporated in vacuo and 
the racemic mixture 13 was obtained in 98% yield (17.2 mg, 0.0284 mmol). 
1
H NMR (500 MHz, 
CD3OD): δ 7.88 – 7.83 (m, 4H), 7.83 – 7.79 (m, 4H), 3.85 (s, 6H), 3.69 (t, J = 6.9 Hz, 4H), 2.16 
– 2.07 (m, 2H), 2.04 - 1.92 (m, 4H), 1.90 – 1.81 (m, 2H), 1.73 (m, 4H), 1.54 – 1.44 (m, 2H), 1.32 
– 1.22 (m, 2H). 13C NMR (125 MHz, CD3OD): δ 171.4, 169.9, 135.5, 133.3, 124.2, 63.9, 54.2, 
38.0, 36.5, 30.7, 29.2, 21.3. HRMS m/z calcd. for C32H39N4O8 [M + H]
+
 607.2762, found 
607.2753 (ESI).  
 
3.2.4 HPLC separation of the racemic mixture 
HPLC analyses were performed on an Agilent 1100 series instrument consisting of a 
quaternary pump, autosampler, diode array detector (DAD) and evaporative light scattering 
detector (ELSD). Astec CHIROBIOTIC
TM
 T (25 cm x 10.0 mm, Supelco Analytical), a chiral 
semi-preparative column was used for separation of enantiomers. A 250 mM ammonium acetate 
buffer pH 4.5, with 70% methanol was used as a mobile phase for separation of protected 13 and 
deprotected 12 racemic mixtures. The mobile phase was degassed by sparging with helium for 
20 min. Instrument parameters were set to the following: flow rate, 2.0 ml/min; injection volume, 
25 µl; DAD, 254 nm; ELSD temperature, 50 ºC; ELSD gain, 5. Acquisition and processing of 
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data was done using ChemStation LC Software (Rev.B.04.02; Agilent Technologies Inc). All 
experiments were performed isocratically. The column was initially washed with methanol and 
equilibrated with the mobile phase for 30 min. For analytical separations, 1 mg/ml solutions of 
13 and 12 were prepared in methanol and water, respectively. For quantitative separations a 5.3 
mg/ml solution of compound 13 was prepared in methanol. Only the DAD detector was used for 
runs involving fraction collection. The middle fraction between peaks of enantiomers was 
discarded to avoid cross contamination. Fractions of each enantiomer were combined and 
evaporated under reduced pressure and moderate heating (40 ºC) to remove all ammonium 
acetate. The 
1
H NMR spectrum of each sample was collected to confirm that ammonium acetate 
had been removed. Each enantiomer obtained was hydrolyzed and purified on a cation exchange 
column as described above in section 3.2.3 for product 12. The purity of each enantiomer was 
judged by HPLC. The amount of sodium bromide in the samples was calculated using a 
calibration plot (Figure A 1). Each enantiomer was tested as an inhibitor of DHDPS. The active 
enantiomer was presumed to be the R,R-isomer, later confirmed by protein crystallography. 
3.2.5 Expression and purification of DHDPS and DHDPR 
DHDPS and DHDPR from C. jejuni were expressed and purified as described previously (37). 
The obtained proteins were concentrated to 0.37 mg/ml for DHDPS and 1.29 mg/ml for DHDPR. 
Enzyme concentrations were determined as reported (37), (CHAPTER 2). The proteins were 
aliquoted and stored at -80 °C. 
3.2.6 Enzyme assays and inhibition studies 
The activity of DHDPS was measured using a coupled assay (38). The initial velocity of the 
DHDPS enzymatic reaction was determined by monitoring the decrease in absorbance at 340 nm 
due to oxidation of NADH (ε340 = 6220 M
-1
cm
-1
) as described previously (37). All kinetic 
measurements were made in 100 mM HEPES buffer at pH 8.0. A one-mL assay contained 0.16 
mM NADH, 0.37 μg of DHDPS, 7.15 μg DHDPR and varying concentrations of ASA (0.066 - 
2.6 mM) and pyruvate (0.20 – 3.7 mM). A 0.0084 mM solution of R,R-bislysine was used in 
inhibition experiments. 0.1 M solutions of L-thialysine and α-methyl-DL-lysine were used for 
inhibition tests. All kinetic studies were carried out at 25 ºC and normal atmospheric pressure. 
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3.2.6.1 Slow-binding kinetic determination 
Inhibition of DHDPS by R,R-bislysine happens in a time-dependent manner, and as such, 
experiments were performed by triggering the reaction by addition of DHDPS. Each progress 
curve was fit to Equation 3.1. 
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where vs and vz are velocities at steady-state and at time zero, kobs is the frequency constant of the 
exponential phase, t is time, d is displacement or finite intercept, [P] is related to the amount of 
product produced. 
3.2.6.2 Steady-state kinetic studies 
DHDPS was preincubated with the inhibitor (and other components of the assay) for 1 min 
and the reaction was started with ASA. This way of conducting the experiments allows the 
inhibitor and the enzyme to form a complex, and the observed rate of the reaction is a steady-
state velocity. The concentration of one substrate was varied, while the concentration of the other 
was kept constant at saturating level (2.6 mM for ASA and 3.7 mM for pyruvate). The models 
for mixed partial (Equation 3.2) and noncompetitive partial inhibition (Equation 3.3) were used 
to fit experimental data with SigmaPlot 10.0 (Systat Software, San Jose, CA).  
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where Vmax is the maximum velocity, KS is the dissociation constant of the ES complex, v is the 
initial velocity. Ki is the inhibition constant, I is the inhibitor concentration, S is the substrate 
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concentration, α and β are proportionality constants. The cooperativity coefficients h' and h 
correspond to R,R-bislysine binding to E and E:pyr respectively (Equation 3.2). For Equation 
3.3, h is a cooperativity coefficient for R,R-bislysine binding to F and F:ASA forms of enzyme. 
Equation 3.4 is the Hill equation for partial inhibition, where vi is the velocity in the presence of 
the inhibitor, v0 is the velocity in the absence of the inhibitor, vi(sat) is the reaction velocity at 
saturating concentrations of inhibitor, and K is an apparent overall dissociation constant. 
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3.3 Results 
3.3.1 Synthesis of α-methyl-DL-lysine 
Synthesis of α-methyl-L-lysine in enantiomerically pure form has been described in the 
literature (39), however for the purposes of performing preliminary inhibition tests, the 
enantiomerically pure form of α-methyl-L-lysine was not required and therefore this method was 
not used. Instead, α-methyl-DL-lysine was synthesized as a racemic mixture using a simpler 
method involving protection of the amino and carboxyl groups, and alkylation by LDA and 
methyl iodide (Scheme 3.1). 
 
Scheme 3.1  Synthesis of α-methyl-DL-lysine. 
Reagents: (a) AcCl, MeOH, 2 h, 65 °C, quant. yield; (b) DIBOC, TEA, THF, 14 h rt, 3 h 50 °C, 
quant. yield; (c) methyl iodide, LDA, THF, 1 h, -78 °C, 54%; (d) 1:1 12M HCl:MeOH, 1h, rt; 
6M HCl (aqueous) 8 h, reflux, 91 %. 
 
3.3.2 L-Thialysine and α-methyl-DL-lysine are weak inhibitors of DHDPS 
L-Thialysine (Figure 3.2) is a very close mimic of L-lysine, having just one replacement of the 
methylene group for sulfur in the side chain. Despite the high structural similarity of lysine and 
thialysine, the latter is a weaker inhibitor with inhibition constants about one order of magnitude 
higher than the corresponding values for L-lysine in experiments with E. coli DHDPS (40). C. 
jejuni DHDPS is even less sensitive to L-thialysine inhibition than the E. coli enzyme, showing 
an apparent IC50 of 2 mM (Figure 3.3). Prior to attempting the synthesis of R,R-bislysine, the 
inhibitory properties of another lysine mimic, α-methyl-DL-lysine (Figure 3.2, Figure 3.3) were 
tested. These results indicate that the methyl group in the α position dramatically decreases 
inhibitory properties of the molecule (IC50
app
 > 10 mM), possibly by preventing proper binding 
molecules of the inhibitor in the proximal allosteric sites.  
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Figure 3.2  L-lysine and lysine analogs.  
 
  
Figure 3.3  Comparison of inhibitory activity of some inhibitors. (●) L-Lysine, (○) L-
thialysine, (■) α-methyl-DL-lysine. Concentrations of ASA and pyruvate 0.23 mM and 0.50 mM 
respectively.  
3.3.3 Synthesis of (±)-bislysine 
(±)-Bislysine was synthesized using a straightforward strategy: double alkylation of protected 
2,5-diamino adipic acid (Scheme 3.2) using 1-bromo-4-chlorobutane followed by introduction of 
ε-amino groups on the side chains. Steps a - e (Scheme 3.2), which describe synthesis of 2,5-
diamino adipic acid as a mixture of diastereomers, had been reported previously (33-35). The 
reported procedures of esterification of carboxyl groups and Boc protection of amino groups (36) 
were effectively applied to 2,5-diamino adipic acid (steps f - g, Scheme 3.2). Along with the 
required dialkylated product 10, monoalkylated side products and products of elimination were 
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observed. In spite of the expected low yield of the alkylation step, (±)-bislysine was obtained in 
amounts sufficient for HPLC separation and inhibition kinetic studies. 
 
Scheme 3.2  Synthesis of (±)-bislysine. 
Reagents: (a) SOCl2, 80 °C, 3 h; (b) Br2, 500 Watt, 12 h, 80 °C; (c) MeOH, 14 h, rt; a-c yield 
87%; (d) potassium phthalimide, DMF, 90 °C, 2 h, 90%; (e) 1:1 48% HBr:AcOH, 14 d, 115 °C, 
96%; (f) AcCl, MeOH, 2 h, 65 °C, quant. yield; (g) DIBOC, TEA, THF, 14 h rt, 3 h 50 °C, 72%; 
(h) 1-bromo-4-chlorobutane, LDA, THF/10% HMPA, 1 h, -78 °C, 12 %; (i) potassium 
phthalimide, DMF, 90 °C, 2 h, 50%; (j) 1:1 48% HBr:AcOH, 3 d, 115 °C, AG 50W-X2, 88%. 
 
3.3.4 HPLC separation of (±)-bislysine 
HPLC analysis confirmed the presence of two enantiomers in the racemic mixture of 
bislysine; two peaks with equal areas were detected (Figure 3.4). The separation was achieved 
using an Astec CHIROBIOTIC
TM
 T chiral column and 250 mM ammonium acetate buffer at pH 
4.5 in 70% methanol as a mobile phase.  
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Figure 3.4  Separation of racemic mixture of bislysine, 12. Astec CHIROBIOTIC
TM
 T 
column; 250 mM ammonium acetate buffer in 70% methanol, pH4.5; flow rate, 2.0 ml/min; 
injection volume, 25 µl; DAD, 254 nm; ELSD temperature, 50 ºC; ELSD gain, 5. 
In order to obtain each individual enantiomer, (±)-bislysine in a partially protected form (Scheme 
3.3) was used in quantitative HPLC separation. This racemic mixture 13 has advantages over the 
deprotected form 12, such as it is UV active, which allowed us to monitor and control the 
collection of fractions, and it has shorter run time (Figure 3.5). 
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Scheme 3.3  Partial deprotection of bislysine precursor 11 to racemic mixture 13. Reagents: (a) 
1:1 DCM:TFA, rt, 1 h. 
 
Figure 3.5  Separation of racemic mixture 13 by HPLC. Astec CHIROBIOTIC
TM
 T column; 
250 mM ammonium acetate buffer in 70% methanol, pH4.5; flow rate, 2.0 ml/min; injection 
volume, 25 µl; DAD, 254 nm. 
 
After removal of ammonium acetate from samples, followed by hydrolysis and purification on an 
ion exchange column (as described in the experimental section 3.2.3), two individual 
enantiomers R,R- and S,S-bislysine were obtained, and the quality of separation was judged by 
HPLC (Figure 3.6, Figure 3.7). 
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Figure 3.6  HPLC chromatogram of R,R-bislysine. Astec CHIROBIOTIC
TM
 T column; 250 
mM ammonium acetate buffer in 70% methanol, pH4.5; flow rate, 2.0 ml/min; injection volume, 
25 µl; DAD, 254 nm; ELSD temperature, 50 ºC; ELSD gain, 5. 
 
 
Figure 3.7  HPLC chromatogram of S,S-bislysine. Astec CHIROBIOTIC
TM
 T column; 250 
mM ammonium acetate buffer in 70% methanol, pH4.5; flow rate, 2.0 ml/min; injection volume, 
25 µl; DAD, 254 nm; ELSD temperature, 50 ºC; ELSD gain, 5. 
 
The samples of enantiomers were obtained as hydrobromide salts. Also, an impurity of sodium 
bromide was detected and calculated for each sample (Figure A 1, Table A 1, page 108). Prior to 
conducting inhibition kinetic studies with R,R-bislysine, it was found that sodium bromide in low 
concentrations (up to 2.0 µM) does not affect the enzymic reaction rate. 
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3.3.5 Slow-onset inhibition 
The analysis of progress curves revealed that R,R-bislysine causes inhibition of DHDPS in a 
time dependent manner (Figure 3.8), where equilibrium between the free inhibitor and enzyme 
species establishes within the first minute.  
 
Figure 3.8  Progress curves of the enzymatic reaction in the presence of increasing 
concentrations of R,R-bislysine: (1) no inhibitor, (2) 0.084 µM, (3) 0.17 µM, (4) 0.42 µM, (5) 
0.84 µM, (6) 1.7 µM. Concentrations of substrates: ASA 2.6 mM, pyruvate 3.7 mM. The curves 
were obtained by starting the reaction with the enzyme.  
Similar to L-lysine (37), R,R-bislysine is a partial inhibitor of C. jejuni DHDPS. At saturating 
concentrations of R,R-bislysine (>1.7 µM) the enzyme still demonstrates 7-10% of the maximal 
activity (Figure A 2). Steady state velocities (slopes of the linear parts of the curves) approach 
the same value when triggering the reaction with either the enzyme or with ASA (Figure A 3) 
and therefore either method is suitable for initiating the enzymatic reaction. The inhibitor does 
not form any covalent bonds with the enzyme, which is supported by crystallographic data 
(Figure 3.12), therefore inhibition caused by R,R-bislysine is reversible. Two major models of 
slow-binding inhibition were described by Walsh (41), where one model describes initial fast 
binding of inhibitor to the enzyme, followed by slow isomerisation of [E:I] complex, and another 
model represents slow binding of inhibitor to the enzyme without isomerisation. The indication 
of the former model is a hyperbolic relationship between kobs and [I], where for the latter model 
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the same relationship is linear. We have discovered a linear relationship between kobs and 
inhibitor concentration (Figure 3.9), where formation of enzyme-inhibitor complexes are slow 
processes. Analysis of equations for slow-binding noncompetitive inhibition derived previously 
(42, 43) explains the linear relationship between kobs and [I] (Scheme A 1, Equation A1, page 
110). Additionally, the overlay of two crystal structures of DHDPS with lysine and R,R-bislysine 
(Figure A 4, page 110) shows that the structures are almost identical and there are no special 
structural features observed that suggests that the enzyme isomerizes upon binding of R,R-
bislysine. This, again, suggests a one-step model of slow-binding inhibition, without 
isomerisation.  
 
Figure 3.9  Relationship between kobs and concentration of R,R-bislysine. Concentrations of 
substrates: ASA 2.6 mM, pyruvate 3.7 mM. The points were obtained by fitting Equation 3.1 to 
progress curves of the reactions started with DHDPS.  
 
Assuming, that R,R-bislysine can bind all enzyme species, demonstrating a simple linear slow-
onset inhibition, Scheme 3.4 is proposed: 
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Scheme 3.4  General scheme of R,R-bislysine inhibition. For this scheme, there is no limit on 
the values of α (and α′), while β (and β′) must be <1 for inhibition. In a pure noncompetitive 
partial inhibition mechanism, α and α′ = 1, therefore Ki3 = Ki4, Ki1 = Ki2, whereas in a mixed 
partial inhibition mechanism, α and α′ ≠ 1 (Ki1 ≠ Ki2, Ki3 ≠ Ki4). 
 
 
3.3.6 Steady-state inhibition studies 
The kinetic analysis of DHDPS inhibition, triggered by the enzyme, has a disadvantage: the 
steady state may not be reached before a significant depletion of substrate, and as such 
parameters (kobs, vz, vs), obtained by fitting Equation 3.1 to experimental progress curves at low 
substrate concentrations, may not be valid. Instead, we have used a short preincubation of the 
enzyme and the inhibitor in the assay buffer followed by addition of ASA to trigger the reaction. 
Equation 3.2 and Equation 3.3 were fit to the obtained steady-state velocities. The data was taken 
when concentration of one substrate was varied and concentration of another substrate was 
maintained at saturating level. Prior to global fitting, Hill coefficients were determined for R,R-
bislysine using Equation 3.4. A series of Hill plots were built over a range of ASA and pyruvate 
concentrations and shown in Appendix A, Figure A 5 and Figure A 6. The average cooperativity 
coefficients of R,R-bislysine with respect to ASA and pyruvate are 1.7 ± 0.1 and 1.6 ± 0.1 
respectively. The cooperativity of substrates does not change in the presence of the inhibitor and 
remains close to one. A mixed partial inhibition model successfully fit the experimental data 
obtained at saturating background concentration of ASA (2.6 mM) over a range of pyruvate 
concentrations (0.20 - 3.7 mM) (Figure 3.10).  
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Figure 3.10  Double-reciprocal plot of data obtained after preincubating enzyme with R,R-
bislysine for 1 min at a constant ASA concentration of 2.6 mM. Concentration of R,R-bislysine: 
(●) 0 µM, (○) 0.084 µM, () 0.17 µM, (□) 0.42 µM, (♦) 0.84 µM, (◊) 1.7 µM. Solid lines are fit 
lines, obtained by global fitting the mixed partial model to the data. Residuals are shown in 
Figure A 7.  
The result of global fitting of a noncompetitive partial inhibition model to the data obtained at 
saturating concentration of pyruvate (3.7 mM) over a range of concentrations of ASA (0.066 - 
2.6 mM) is presented in Figure 3.11.  
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Figure 3.11  Double-reciprocal plot of data obtained after preincubating enzyme with R,R-
bislysine for 1 min at a constant pyruvate concentration of 3.7 mM. Concentration of R,R-
bislysine: (●) 0 µM, (○) 0.084 µM, () 0.17 µM, (□) 0.42 µM, (♦) 0.84 µM, (◊) 1.7 µM. Solid 
lines are fit lines, obtained by global fitting the noncompetitive partial model to the data. 
Residuals are shown in Figure A 8.  
For the mixed partial inhibition model (with respect to pyruvate) the best fit was produced when 
cooperativity coefficients of R,R-bislysine binding to the E and E:pyr forms of the enzyme were 
equal 1.0 and 1.6 respectively (where the coefficient 1.6 was found by the graphical method and 
the coefficient 1.0 was found as a result of global fitting). Substitution of the average 
cooperativity coefficient of R,R-bislysine with respect to ASA, found by the graphical method 
(1.7 ± 0.1) in Equation 3.3 produces the best fit for the noncompetitive partial model. Based on 
information of L-lysine inhibition (37), the models of uncompetitive partial inhibition (where 
pyruvate is a varied substrate) and mixed partial model (where ASA is a varied substrate) were 
considered as well. Based on the comparison of statistical parameters (R
2
) and analysis of 
diagnostic plots (Dixon and Cornish-Bowden plots are not shown) we conclude that, unlike L-
lysine, R,R-bislysine binds (and demonstrates inhibitory properties) to both the free enzyme form 
E and the enzyme-pyruvate complex E:pyr with different affinities supporting the choice of the 
mixed partial model of inhibition. When ASA is a variable substrate, both mixed partial and 
noncompetitive partial models fit the data fairly well, but the noncompetitive partial model was 
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given a preference as a model providing a good fit with fewer variables (α = 1). The results of 
global fitting are summarized in the Table 3.1. 
Table 3.1  R,R-bislysine inhibition kinetic results for C. jejuni DHDPS
a
. 
Kinetic model Mixed partial 
Noncompetitive 
partial 
Variable substrate Pyruvate ASA 
hE 1.0 ± 0.2  
hE:pyr 1.6 ± 0.1  
hF  1.7 ± 0.1 
hF:ASA  1.7 ± 0.1 
Ki1, nM 240  50  
Ki2, nM 170 ± 70  
Ki3, nM  200  20 
Ki4, nM  200  20 
a
These inhibition constants correspond to those in Scheme 3.4. 
 
3.4 Discussion 
Inhibition studies of DHDPS with L-thialysine showed that its apparent IC50 is approximately 
30 times higher than that of lysine. The substitution of C-4 of lysine with sulfur slightly affects 
the length and volume of the side chain due to the larger atomic radius of sulfur, as well as the 
pKa of the terminal amino group, which is lower than the pKa of the corresponding group in 
lysine (9.52 and 10.53 respectively (44, 45)). α-Methyl-DL-lysine is a very poor inhibitor of 
DHDPS with an apparent IC50 value higher than 10 mM, which suggests that a steric clash 
between methyl groups prevents proper binding of this molecule. These results indicate that the 
allosteric site of C. jejuni DHDPS is very selective and proper distance between α carbons is 
required for inhibitory activity of ''bridged'' inhibitors, which is supported by these studies with 
R,R-bislysine. 
Until this present work there were no inhibitors reported having stronger inhibitory properties 
than the natural inhibitor L-lysine. R,R-bislysine is the first inhibitor of DHDPS that is active in 
the submicromolar concentration range. In this study we have proven that it is possible to design 
a potent allosteric inhibitor of DHDPS mimicking binding of two lysine molecules in the 
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adjacent allosteric sites. The results of this study open new perspectives into the design and 
synthesis of allosteric inhibitors of DHDPS from different organisms. A straightforward, non-
stereoselective synthetic route of bislysine synthesis was developed to confirm the validity of an 
idea that ''bridging'' of two lysine molecules would make a better inhibitor.  
R,R-bislysine is a partial inhibitor of C. jejuni DHDPS. The minimal residual activity of the 
enzyme inhibited by R,R-bislysine is similar to that of L-lysine (7 - 10%) (37). Binding of R,R-
bislysine is cooperative and the values of Hill coefficients (1.6 and 1.7) indicate that 
simultaneous binding of one molecule of R,R-bislysine at one pair of adjacent allosteric sites in 
the dimer promotes binding of another molecule of R,R-bislysine at the allosteric site of the other 
dimer. In other words, C. jejuni DHDPS demonstrates inter-dimer cooperativity upon binding of 
R,R-bislysine. The cooperativity coefficients of R,R-bislysine were introduced into equations of 
inhibition models. The mixed partial and noncompetitive partial models provide the best fit of 
the data, where the varied substrates are pyruvate and ASA, respectively. Analyzing the 
inhibition constants, presented in the Table 3.1, we conclude that R,R-bislysine binds with 
similar affinity to all enzyme species, with an average inhibition constant 200 nM. The inhibitory 
activity of R,R-bislysine is approximately 310 times higher than that of L-lysine, which allows us 
conclude that the design of a molecule that fits both adjacent allosteric sites in the dimer is a 
beneficial strategy in the development of new inhibitors of DHDPS. The crystal structure of C. 
jejuni DHDPS with R,R-bislysine bound at the allosteric site was solved at 2.2 Å resolution. The 
electron density confirms that the inhibitor in the allosteric site has R configuration of both 
stereogenic centers (Figure 3.12) (Conly et al., Unpublished work). Similar to lysine, R,R-
bislysine makes hydrogen bonds with Ser51, Ala52, His59, Asn84', Glu88', Tyr110 and Ser51', 
Ala52', His59', Asn84, Glu88, Tyr110' and cation-π interactions with His56 and His56' (Figure 
3.10). The distances between terminal amino groups of R,R-bislysine and the backbone 
carbonyls of Leu54 and Leu54' are longer compared to L-lysine in C. jejuni DHDPS (4.0 – 4.2 
Å), and they are no longer able to make hydrogen bonds. The overlay of R,R-bislysine and two 
L-lysines bound in C. jejuni DHDPS shown in Figure 3.13.  
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Figure 3.12  The crystal structure of C. jejuni DHDPS with R,R-bislysine bound at the 
allosteric site.  
 
 
Figure 3.13  The overlay of crystal structures of R,R-bislysine and L-lysine bound at the 
allosteric site of C. jejuni DHDPS. L-Lysine is blue and R,R-bislysine is orange.  
The loss of entropy upon binding of one R,R-bislysine molecule is lower than that of two 
molecules of L-lysine, which increases the total entropy of the system, and decreases the free 
energy of the system. The latter is likely the reason for the significant increase in an inhibitory 
activity of R,R-bislysine. The two carbon bridge in the molecule of R,R-bislysine does not make 
any polar or nonpolar contacts with the enzyme (does not change the enthalpy factor), which 
supports the assumption that binding affinity increases mostly due to the entropy factor. 
S,S-bislysine and R,S-bislysine (meso-bislysine, obtained similar to (±)-bislysine from the 
product 10b, described in 3.2.3) were tested in the assay and apparent IC50 values were 
estimated: ~50 µM and ~2 mM correspondingly. The low inhibitory activity of the meso 
compound is explained by its structural similarity to both L-lysine (a good inhibitor) and D-lysine 
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(a poor inhibitor (16)). S,S-bislysine is structurally similar to D-lysine and therefore its inhibitory 
activity should be lower than that of the meso compound. While it is possible for S,S-bislysine to 
inhibit DHDPS, the observed IC50 value being lower than that of the meso compound can be due 
to a slight contamination of S,S-bislysine with R,R-bislysine. Even a small amount of R,R-
bislysine (below the HPLC detection limit) would decrease the IC50 of S,S-bislysine. 
The design of the two carbon bridge in R,R-bislysine was a successful strategy to improve the 
effectiveness of the inhibitor; however its ability to rotate about the carbon bridge likely reduces 
its binding efficiency. The next step would be to design an inhibitor with ''fixed'' conformation 
and less freedom of rotation, and to decrease polarity of the molecule by replacing the carboxyl 
and amino groups with suitable isosteres.  
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CHAPTER 4.   MUTAGENESIS STUDY OF DIHYDRODIPICOLINATE 
SYNTHASE FROM CAMPYLOBACTER JEJUNI: HOW MUTATIONS IN THE 
ALLOSTERIC SITE AFFECT BINDING OF NONCOMPETITIVE INHIBITORS 
4.1 Introduction 
Antibiotic resistance of bacteria is a big concern that has emerged in the latter half of the last 
century (1). Therefore the discovery of new targets for antibiotic design is one of the primary 
tasks of medicinal chemistry (2). Inhibitors of bacterial cell wall synthesis are proven to be 
successful antibiotics (3). Bacterial cell walls require meso-diaminopimelate (or L-lysine for 
some organisms) for cross-linking of peptidoglycan chains (4, 5), therefore the enzymes of the 
meso-diaminopimelate and L-lysine biosynthetic pathways are potential targets for drug 
development (6-8).  
Dihydrodipicolinate synthase is an enzyme of the bacterial meso-diaminopimelate and L-
lysine biosynthetic pathway, also found in plants and some fungi (9-11). It catalyses the aldol 
condensation of pyruvate and (S)-aspartate-β-semialdehyde (ASA) into an unstable heterocyclic 
product, (4S)-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate (HTPA), which spontaneously 
dehydrates into dihydrodipicolinate (DHDP) (12, 13). Genetic studies showed that DHDPS is an 
essential enzyme for many bacterial species (14-18). The assumption is that effective inhibition 
of DHDPS will impair bacterial cell wall synthesis. To prove this hypothesis a number of 
research groups are working on design and synthesis of inhibitors of DHDPS (7, 9, 19-27). 
DHDPS is an allosteric enzyme and its natural allosteric modulator is L-lysine. DHDPS from 
plants are inhibited by L-lysine in low micromolar IC50 range (28-30). DHDPS from Gram-
negative bacteria are moderately or weakly inhibited by L-lysine (micromolar or millimolar IC50 
values) (31-33). DHDPS from Gram-positive bacteria show no inhibition by L-lysine (34-37). 
The reason for this difference is a distinct variation in structural organization of the allosteric 
sites in DHDPS from Gram-positive bacteria.  
The proposed catalytic triad (Thr44, Tyr107', Tyr133), the key residue required for Schiff 
base formation (Lys161), and a residue responsible for ASA binding, Arg138, (E. coli 
numbering) are conserved for all DHDPS (12, 38, 39). Several crystal structures of DHDPS with 
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lysines bound at the allosteric sites have been obtained (E. coli, PDB code 1YXD; P. aeruginosa, 
3PUO; V. vinifera, 4HNN; C. jejuni, 4M19; S. pneumoniae, 4FHA), and the residues responsible 
for lysine binding were determined (12, 40, 41). A few examples of homologous amino acids 
forming the allosteric sites of DHDPS from Gram-negative, Gram-positive bacteria, and plants 
are listed in Table 4.1. A sequence alignment of DHDPS from different groups of species reveals 
conserved (Tyr106) and variable (Ser48, Ala49, Leu51, His53, His56, Asn80', Glu84') allosteric 
site residues (Figure B 1, Figure B 2 and Figure B 3, pages 139-141). Tyr106 participates in 
lysine binding by donating a hydrogen bond to the carboxyl group of L-lysine, while Tyr 107 is a 
part of the catalytic triad. It is likely that signal transduction happens via Tyr106 movement upon 
binding of lysine, where a shift of Tyr106 affects the position of catalytic Tyr107 and alters the 
catalytic activity of the enzyme (Figure 4.1). Mutation of Tyr106 to Phe would reduce the 
binding affinity of lysine and decrease or eliminate signal transduction to the active site.  
 
 
Figure 4.1  The element of signal transduction in DHDPS from allosteric to active site. 
Crystal structure of C. jejuni DHDPS with two L-lysine molecules bound at the allosteric site. E. 
coli numbering is shown in blue and C. jejuni numbering is shown in black. Dotted lines 
represent hydrogen bonds.  
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Table 4.1  Examples of allosteric site amino acid residues in different species
a
. 
Allosteric site 
residues in E. coli 
DHDPS 
Ser48
b
 Ala49
b
 Leu51
b
 His53 His56 Asn80' Glu84' Tyr106 
Interactions with 
lysine in E. coli 
DHDPS 
H-bond 
with ε-
amino 
group 
H-bond 
with α-
amino 
group 
H-bond 
with ε-
amino 
group 
cation-π 
interaction 
H-bond 
with ε-
amino 
group 
H-bonds 
with α-
amino and 
carboxyl 
groups 
H-bond 
with α-
amino 
group 
H-bond 
with 
carboxyl 
group 
Homologous 
residues in 
different species 
Gram-negative: 
C. jejuni 
N. meningitides 
R. typhi 
S. meliloti 
M. mediterranea 
 
 
 
 
Ser 
Ser 
Ala 
Ser 
Ala 
 
 
 
 
Ala 
Ala 
Asn 
Ala 
Ala 
 
 
 
 
Leu 
Leu 
Leu 
Leu 
Leu 
 
 
 
 
His 
Val 
Phe 
Lys 
Asp 
 
 
 
 
His 
His 
Tyr 
His 
Ala 
 
 
 
 
Asn 
Asn 
Asn 
Asn 
Asn 
 
 
 
 
Glu 
Glu 
Tyr 
Glu 
Lys 
 
 
 
 
Tyr 
Tyr 
Tyr 
Tyr 
Tyr 
Plants: 
V. vinifera 
N. silvestris 
Z. mays 
T. aestivum 
T. cacao 
 
Gly 
Gly 
Gly 
Gly 
Gly 
 
Gln 
Gln 
His 
His 
Gln 
 
Met 
Met 
Met 
Met 
Met 
 
Trp 
Trp 
Trp 
Trp 
Trp 
 
His 
His 
His 
His 
His 
 
Asn 
Ile 
Asn 
Asn 
Asn 
 
Glu 
Glu 
Glu 
Glu 
Glu 
 
Tyr 
Tyr 
Tyr 
Tyr 
Tyr 
Gram-positive: 
B. anthracis 
S. aureus 
C. glutamicum 
L. ruminis 
C. botulinum 
 
Ser 
Ser 
Ser 
Gly  
Ala 
 
Pro 
Pro 
Pro 
Pro 
Thr 
 
Leu 
Leu 
Thr 
Leu 
Met 
 
Ser 
Thr 
Ala 
Glu 
Glu 
 
Lys 
Lys 
Lys 
Lys 
Arg 
 
Asn 
Asn 
Asn 
Asn 
Asn 
 
Ala 
Lys 
Thr 
Thr 
Ala 
 
Tyr 
Tyr 
Tyr 
Tyr 
Tyr 
a 
sequence alignments are shown in Appendix B, Figure B 1, Figure B 2 and Figure B 3. 
b
 interactions with the main chain. 
His56 is often present in Gram-negative bacteria and it is a conserved residue in plant 
DHDPS, but in Gram-positive bacteria this position is mostly occupied by Lys (Table 4.1); the 
last is likely one of the reasons for the noted insensitivity to allosteric regulation by lysine (37). 
Lys56 in Gram-positive bacterial DHDPS points into the allosteric site, creating a steric clash 
with the allosteric inhibitor. Additionally, the repulsion of positively charged ε-amino groups 
would prevent lysine binding. His53 is not a conserved residue in DHDPS from Gram-negative 
and Gram-positive bacteria, but plant DHDPS contain conserved tryptophan in the same 
position. The replacement of Trp53 for Arg in mutagenesis studies on plant DHDPS resulted in 
complete insensitivity of the enzyme to lysine inhibition (42). Apparently, Trp53 in plants makes 
a significant contribution to the increased affinity of the allosteric site to L-lysine.  
Campylobacter jejuni is a Gram-negative pathogen found in humans and animals (43, 44). 
The kinetic properties and lysine inhibition kinetics of DHDPS from C. jejuni have been 
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described previously (33). The remarkable inhibitory activity of R,R-bislysine against C. jejuni 
DHDPS raises interest in how mutations in the allosteric site would affect binding of the natural 
allosteric inhibitor L-lysine and the potent synthetic inhibitor R,R-bislysine.  
Displacements of His56 and His59 (the corresponding residues in E. coli DHDPS are His53 
and His56) were observed upon lysine binding, which is shown in the DHDPS crystal structures 
overlay (Figure 4.2). As a result of lysine binding, His56 and His59 move toward the center of 
the allosteric site creating a new hydrogen bond network. 
 
Figure 4.2  Overlay of C. jejuni DHDPS structures: DHDPS-pyruvate complex, PDB ID 
4LY8 (green) and DHDPS-pyruvate with lysine bound at the allosteric site, PDB ID 4M19 
(purple).   
In this work we show how mutations of Y110, His56 and His 59 affect the catalytic activity of 
C. jejuni DHDPS, as well as how the inhibitory ability of noncompetitive inhibitors (L-lysine, 
R,R-bislysine) changes when they bind to the modified allosteric site.  
 
4.2 Materials and Methods 
Pyruvate, L-lysine and NADH were obtained from Sigma-Aldrich Canada, Ltd (Oakville, 
ON), (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) was purchased from BDH 
(Mississauga, ON). (S)-Aspartate-β-semialdehyde (ASA) was synthesized according to the 
reported procedure (45). The concentration of each newly prepared work solution of ASA was 
determined using the DHDPS-DHDPR coupled kinetic assay (33, 46), in the presence of excess 
NADH. R,R-Bislysine was synthesized as described in Chapter 3 (3.2.3). 
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4.2.1 Site-directed mutagenesis 
Y110F, H56A, H56N, H59A, and H59N mutations were generated using KAPA HiFi
TM
 PCR 
Kit (Kapa Biosystems) according to manufacturer’s recommendations. Mutagenic primers were 
designed to introduce the required mutations:  
5'-GATTTTAAGTGTGGCGCCGTTTTATAATAAACCTACGCAACAAG-3',  
5'-GTGCAACTTTAACCGCTGAAGAACATAGAACATGCATAGAAATAGCC-3', 
5'-GTGCAACTTTAACCAATGAAGAACATAGAACATGCATAGAAATAGCC-3', 
5'-CTTTAACCCATGAAGAAGCTAGAACATGCATAGAAATAGCCGTTG-3', 
5'-CTTTAACCCATGAAGAAAATAGAACATGCATAGAAATAGCCGTTG-3'. 
Mutations shown in bold introduce phenylalanine for Y110F, alanine and asparagine for H56A 
and H56N, alanine and asparagine for H59A and H59N respectively. Additional silent mutations 
(shown in bold italic) were made to generate new restriction sites (underlined) NarI (Y110F) and 
NsiI (H56A, H56N, H59A, H59N) for the purpose of screening E. coli XL1-Blue transformants. 
Isolated plasmid DNA from selected clones was sequenced by the DNA Technologies Unit of 
the National Research Council, Saskatoon, Canada.  
4.2.2 Expression and purification of mutants and DHDPR 
Y110F, H56A, H56N, H59A, H59N and DHDPR proteins were expressed, purified and 
concentrated to 1.2, 0.81, 1.0, 0.28, 0.88 and 1.29 mg/ml respectively as previously described for 
Wt-DHDPS from C. jejuni (33). The proteins were aliquoted and stored at -80 °C. 
4.2.3 Enzyme assay 
The activity of mutants was measured using a coupled assay (46). The assay was conducted in 
100 mM HEPES buffer at pH 8.0 and 25 °C as previously described for the wild-type enzyme 
(33). The amounts of Y110F, H56A, H56N, H59A and H59N used in the assay were 1.2 µg, 0.81 
µg, 1.0 µg, 1.4 µg and 0.88 µg respectively. The obtained kinetic data were fitted to the rate 
Equation 4.1 (ping-pong kinetic mechanism) using SigmaPlot 10.0 (Systat Software, San Jose, 
CA): 
                                                                                       (4.1) 
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where Vmax is the maximum velocity, KM(A) and KM(B) are the Michaelis-Menten constants for 
two substrates, A and B are the concentrations of the substrates, and v is the initial velocity. 
Lysine inhibition studies were conducted at constant saturating level of one of the substrates 
(2.5 mM for ASA and 3.7 mM for pyruvate). The models for the mixed partial (α ≠ 1, 0 < β < 1), 
noncompetitive partial (α = 1, 0 < β < 1) (Equation 4.2) or uncompetitive partial inhibition (0 < β 
< 1) (Equation 4.3) were used to fit experimental data, as indicated in the results section,  
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where Ki is the inhibition constant, [I] is the inhibitor concentration, S is the substrate 
concentration, α and β are proportionality constants. Cooperativity coefficients h' and h are for 
lysine binding to Schiff-base enzyme and Schiff-base-ASA complex (Equation 4.2). For 
Equation 4.3, h is the cooperativity coefficient for lysine binding to the E:pyr form of the 
enzyme. Equation 4.4 is the Hill equation for partial inhibition, where vi is the velocity in the 
presence of the inhibitor, v0 is the velocity in the absence of the inhibitor, vi(sat) is the reaction 
velocity at saturating concentrations of inhibitor, and K is an apparent overall dissociation 
constant. Equation 4.5 is the Hill equation for cooperative substrate binding, where vi is velocity, 
Vmax is maximal apparent velocity at saturated concentration of the variable substrate, K' is an 
apparent overall affinity constant of the substrate, n is Hill coefficient of the substrate, and [S] is 
the concentration of the variable substrate. When cooperativity of ASA is noticed, Equation 4.2 
should be modified by introducing the cooperativity coefficient of ASA n, and therefore terms 
[S] and Ks would be changed to [S]
n
 and Ks
n
 respectively.  
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The enzymatic reaction was triggered by the addition of DHDPS in lysine inhibition studies, 
while in R,R-bislysine inhibition experiments DHDPS was preincubated with the inhibitor within 
one minute, and the reaction was triggered with ASA. This technique helps to avoid a time-
dependent phase of slow-binding, so R,R-bislysine would form a complex with the enzyme prior 
to reaction initiation.  
The inhibition by L-lysine and R,R-bislysine were tested in the range of lysine concentration 
(0 - 40 mM) and R,R-bislysine concentration (0 – 3.4 µM) at saturating concentration of pyruvate 
and a near-KM concentration of ASA.  
 
4.3 Results and Discussion 
4.3.1 Ping-pong kinetics of mutants 
Kinetic data for Y110F, H56A, H56N, H59A, and H59N were obtained and the ping-pong 
model (Equation 4.1) was fitted to the experimental values. Similar to Wt-DHDPS, all mutants 
display a ping-pong mechanism, and demonstrate approximately half of the enzymatic activity of 
wild-type (Table 4.2, Appendix B, Figure B 4 - Figure B 13, pages 142-146). 
Table 4.2  Kinetic constants for Y110F, H56A, H56N, H59A, H59N in comparison with Wt-
DHDPS. 
 KM(pyr), mM KM(ASA), mM kcat, s
-1
 kcat/KM(pyr), M
-1
s
-1
 kcat/KM(ASA), M
-1
s
-1
 
Wt
a 
0.35 ± 0.02 0.16 ± 0.01 76 ± 1 (2.2 ± 0.1) × 10
5
 (4.8 ± 0.3) × 10
5
 
Y110F 0.19 ± 0.01 0.12 ± 0.01 33 ± 1 (1.8 ± 0.1) × 10
5
 (2.7 ± 0.1) × 10
5
 
H56A 0.26 ± 0.02 0.16 ± 0.01 40 ± 1 (1.5 ± 0.1) × 10
5
 (2.5 ± 0.1) × 10
5
 
H56N 0.39 ± 0.02 0.20 ± 0.01 54 ± 1 (1.4 ± 0.1) × 10
5
 (2.6 ± 0.2) × 10
5
 
H59A 0.31 ± 0.02 0.15 ± 0.01 31 ± 1 (1.0 ± 0.1) × 10
5
 (2.1 ± 0.2) × 10
5
 
H59N 0.40 ± 0.02 0.12 ± 0.01 36 ± 1 (0.9 ± 0.1) × 10
5
 (2.9 ± 0.2) × 10
5
 
a 
Reference (33) 
 
4.3.2 L-lysine inhibition of mutants 
The lysine IC50 for Y110F was found to be approximately 40 mM (Figure 4.3), which 
indicates that Y110F mutation dramatically changes the ability of the enzyme to be inhibited by 
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lysine. This mutation makes the enzyme insensitive to L-lysine regulation at its physiological 
concentrations.  
 
Figure 4.3  (A) Lysine inhibition curve for Y110F, (ASA 0.12 mM, pyruvate 3.7 mM); (B) 
Comparison of lysine inhibition for Y110F (●) and wild-type (◊), (ASA 0.16 mM, pyruvate 3.5 
mM).  
His56 does not make hydrogen bonds with a bound allosteric lysine directly, but it 
participates in a hydrogen bond network in the allosteric site. Also, His56 is situated within a 
favorable distance to make a cation-π interaction with the ε-amino group of L-lysine. Mutation of 
His56 to Ala would eliminate all polar interactions with the side chain. Mutation of His56 to Asn 
might maintain hydrogen-bonding interactions, but will not be able to make the cation-π 
interaction with lysine. His56A and His56N mutations are therefore expected to decrease the 
binding affinity of lysine. Lysine inhibition studies for these mutants were carried out in the 
range of lysine concentration 0 – 5.0 mM, at saturating background concentration of one of the 
substrates. Lysine binds cooperatively to both mutants and a series of Hill plots were built at 
various concentrations of pyruvate and ASA (Appendix B, Figure B 14 – Figure B 17, pages 
147-148). The average cooperativity coefficients of lysine were 2.0 ± 0.2 and 1.6 ± 0.4 for 
H56A, and 2.0 ± 0.3 and 2.3 ± 0.3 for H56N, where the first value corresponds to the condition 
when ASA is varied substrate and the second when pyruvate is varied. A slight curvature in the 
Lineweaver–Burk plots (Figure 4.5 and Figure 4.7) indicates cooperativity of ASA binding in the 
presence of lysine. The same observation has been reported for wild-type DHDPS (33). The 
average cooperativity coefficients of ASA for H56A and H56N mutants in the presence of lysine 
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were found to be 1.2 ± 0.1 and 1.3 ± 0.1, respectively (Appendix B, Figure B 18, Figure B 19, 
pages 149-150). The cooperativity coefficients of lysine and ASA found by graphical methods 
are in agreement with the values obtained by global fitting (Table 4.3). The uncompetitive partial 
and mixed partial models provided the best fit of the experimental data of L-lysine inhibition for 
the H56A mutant (Figure 4.4, Figure 4.5, Appendix B, Figure B 20 and Figure B 21, page 151). 
For the H56N mutant, the uncompetitive partial model fits well the experimental data with 
respect to pyruvate (Figure 4.6, Appendix B, Figure B22, page 151), and the best fit with respect 
to ASA was obtained when the mixed partial model was simplified to noncompetitive partial (α 
= 1, Equation 4.2) (Figure 4.7, Appendix B, Figure B 23, page 152).  
   
Figure 4.4  Double-reciprocal plot of data obtained at a constant ASA concentration of 2.5 
mM for H56A. Concentration of lysine: (●) 0 mM, (○) 0.080 mM, () 0.10 mM, (□) 0.15 mM, 
(♦) 0.20 mM, (◊) 0.50 mM, () 5.0 mM. Solid lines are fit lines, obtained by global fitting the 
uncompetitive partial model (Equation 4.3, 0 < β < 1) to the data. Residuals are shown in Figure 
B 20.  
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Figure 4.5  Double-reciprocal plot of data obtained at a constant pyruvate concentration of 
3.7 mM fit to the mixed partial inhibiton model (Equation 4.2, 1 < α < ∞, 0 < β < 1) for H56A. 
Concentration of lysine: (●) 0 mM, (○) 0.080 mM, () 0.10 mM, (□) 0.15 mM, (♦) 0.20 mM, 
(◊) 0.50 mM, () 5.0 mM. Solid lines are fit lines. Residuals are shown in Figure B 21.  
 
 
Figure 4.6  Double-reciprocal plot of data obtained at a constant ASA concentration of 2.5 
mM for H56N. Concentration of lysine: (●) 0 mM, (○) 0.080 mM, () 0.10 mM, (□) 0.15 mM, 
(♦) 0.20 mM, (◊) 0.50 mM, () 5.0 mM. Solid lines are fit lines, obtained by global fitting the 
uncompetitive partial model (Equation 4.3, 0 < β < 1) to the data. Residuals are shown in Figure 
B 22.  
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Figure 4.7  Double-reciprocal plot of data obtained at a constant pyruvate concentration of 
3.7 mM fit to the noncompetitive partial inhibiton model (Equation 4.2, α = 1, 0 < β < 1) for 
H56N. Concentration of lysine: (●) 0 mM, (○) 0.080 mM, () 0.10 mM, (□) 0.15 mM, (♦) 0.20 
mM, (◊) 0.50 mM, () 5.0 mM. Solid lines are fit lines. Residuals are shown in Figure B 23. 
 
His59 forms a hydrogen bond with the ε-amino group of lysine and therefore replacement of 
it with Ala or Asn would reduce the binding ability of lysine. Asparagine could donate or accept 
a H-bond, but the pKa value of this residue is different from histidine. The lysine inhibition 
curves for H59A and H59N mutants are shown in Figure 4.8.   
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Figure 4.8  Lysine inhibition curves for H59A () and H59N (○) at saturating concentration 
of pyruvate 3.7 mM, and 0.15 mM ASA.  
The apparent IC50 values of L-lysine for H59A and H59N were estimated ~25 mM and ~10 mM 
respectively. Significant decrease in lysine inhibitory activity was expected, and the fact that the 
IC50 value of H59N is smaller than that of H59A is in agreement with the suggestion that H59N 
is able to make more polar contacts with the inhibitor than H59A. The lysine inhibition results 
for the mutants are summarized in Table 4.3.  
Table 4.3  Lysine inhibition kinetics results (Ki or IC50 
app) for the DHDPS mutants. 
Kinetic parameters Wt
e
 Y110F H56A H56N H59A H59N 
hE:pyr, lysine
a
  2.6 ± 0.1  2.1 ± 0.3 2.0 ± 0.1   
hF, lysine
a
 2.3 ± 0.2  1.5 ± 0.2 1.7 ± 0.3   
hF:ASA, lysine
a
 2.8 ± 0.2  2.0 ± 0.3 1.9 ± 0.2   
h, ASA
a
 1.1 ± 0.1  1.2 ± 0.1 1.3 ± 0.1   
Ki (1), mM
b
 0.069 ± 0.001  0.31 ± 0.03 0.17 ± 0.01   
Ki (2), mM
c
 0.045 ± 0.003  0.21 ± 0.04 0.16 ± 0.01   
Ki (3), mM
d
 0.072 ± 0.009  0.37 ± 0.10 0.16 ± 0.01   
IC50 
app
, mM  ~40*   ~25* ~10* 
*
due to very weak lysine inhibition, only IC50
app
 was estimated 
a
 cooperativity coefficients were found by global fitting  
b
 Ki (1) inhibition constant of binding to E:pyr complex 
c
 Ki (2) inhibition constant of binding to F (Schiff base enzyme form) 
d
 Ki (3) inhibition constant of binding to F:ASA complex 
e
 Reference (33) 
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4.3.3 R,R-bislysine inhibition 
R,R-bislysine is a potent submicromolar inhibitor of wild type C. jejuni DHDPS with an 
average Ki of 200 nM (Chapter 3). R,R-Bislysine resembles two molecules of L-lysine connected 
via a carbon-carbon bridge (Figure 4.9). The initial assumption was that because of the structural 
similarity of lysine and R,R-bislysine, the latter would demonstrate similar inhibition behavior 
with DHDPS mutants as L-lysine, but with proportionally higher binding affinities. 
 
Figure 4.9  Molecule of R,R-bislysine.  
Surprisingly, strong inhibition by R,R-bislysine was observed for mutants which were almost 
insensitive to lysine inhibition. The inhibitory efficiency of R,R-bislysine toward Y110F was 
almost as high as for wild-type DHDPS (Figure 4.10). R,R-bislysine binds to Y110F 
approximately 100,000 times stronger than lysine. 
 
Figure 4.10  R,R-bislysine inhibition curves for Wt-DHDPS (○) and Y110F (●) at 3.7 mM 
pyruvate and 0.1 mM ASA.   
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Also, strong inhibition by R,R-bislysine was observed for H56A, H56N and H59N, where 
apparent IC50 values of the inhibitor are within the range 0.2 – 0.6 µM (Figure 4.11). The lowest 
binding affinity of R,R-bislysine was observed for H59A (IC50
app
 ≈ 4 µM), yet it still binds to this 
mutant approximately 6,250 times stronger than lysine.  
 
Figure 4.11  R,R-bislysine inhibition curves for Wt-DHDPS (●), H59N (○), H59A (), H56A 
(◊), and H56N (□) at 3.7 mM pyruvate and 0.1 mM ASA.   
The inhibition results have shown that Tyr110 and His59 are important for lysine binding and 
inhibition, but they are not crucial for R,R-bislysine. The high inhibitory effectiveness of R,R-
bislysine against Y110F indicates that Tyr110 is not the only essential component of the signal 
transduction system in C. jejuni DHDPS. The replacement of His56 for Ala and Asn has 
decreased binding affinity of lysine approximately by five and three times, respectively, however 
they do not significantly change apparent IC50 of R,R-bislysine. The R,R-bislysine inhibition 
curve for H56N has a distinct partial inhibition pattern (Figure 4.11) and shows more than 20% 
of residual activity under conditions employed, while wild-type, Y110F, H59A and H56A 
demonstrate less than 20% of residual activity at saturating levels of R,R-bislysine. The 
properties of the amino acid side chain in position 56 (53 in E. coli DHDPS) may be responsible 
for the partial inhibition profile. Atkinson et al. (41) pointed out the importance of a Trp residue 
in the corresponding position in plant DHDPS. Replacement of Trp for His in bacterial DHDPS 
changes the exposure of the allosteric site to solvent (41).  
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The results suggest that lysine inhibition is extremely dependent on the amount of polar 
contacts with residues in the allosteric site (Tyr110 and His59 in particular), but inhibition by 
R,R-bislysine remains strong even with fewer polar interactions.  
  
4.3.4 Conclusions 
The Y110F, H59A, H59N, H56A and H56N mutations in the allosteric site of C. jejuni 
DHDPS cause a decrease in catalytic activity of the enzyme, which is approximately half of 
activity of wild-type in each case. Y110F, H59A and H59N mutations make the enzyme almost 
insensitive to L-lysine inhibition. The binding affinity of lysine to H56A and H56N decreases by 
five and three times respectively when compared to the wild-type. However, R,R-bislysine 
inhibition of Y110F, H59N, H56A and H56N is comparable to that of wild-type, showing 
apparent IC50 values in the 0.2 – 0.6 µM range. H59A is less sensitive to R,R-bislysine inhibition, 
and its binding affinity decreases almost ten-fold relative to the wild-type. The R,R-bislysine 
inhibition results suggest some possible modifications that can be made to R,R-bislysine 
molecule. For instance, hydrogen bonding between Tyr110 and the carboxyl group of the 
inhibitor is not essential for inhibition and, therefore, can be replaced. On the other hand, 
hydrogen bonding between His59 and ε-amino group of the inhibitor plays an important role in 
inhibition.  
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CHAPTER 5.  DISCUSSION, CONCLUSIONS AND FUTURE WORK 
5.1 From L-lysine and weak allosteric inhibitors of DHDPS to potent R,R-bislysine 
The present study is a comprehensive analysis of an allosteric enzyme DHDPS and its 
allosteric inhibitors. A detailed lysine inhibition study has been presented for the first time with 
C. jejuni DHDPS. The results suggest that C. jejuni DHDPS is several times more sensitive to 
lysine inhibition than E. coli DHDPS (1) and has inhibition constants 69 ± 1, 45 ± 3, and 72 ± 9 
µM, for when lysine binds to the E:pyr, F, and F:ASA complexes, respectively. Comparison of 
mixed partial and uncompetitive partial kinetic models for lysine inhibition with respect to 
pyruvate allowed us to conclude that lysine is an uncompetitive partial inhibitor, which is in 
agreement with work of Karsten (1) and Soares da Costa et al. (2), who studied E. coli DHDPS. 
This kinetic model does not exclude the capability of lysine to bind to the free enzyme form E, 
but rather indicates that if this E:I complex exists, it doesn’t affect binding of the first substrate 
pyruvate. The results of lysine inhibition with respect to ASA indicates a mixed partial model of 
inhibition (which is a type of noncompetitive inhibition where binding affinities for lysine of F 
and F:I complexes are different). This conclusion, again in agreement with the work of Karsten 
(1), and somewhat different from the results of Gerrard and co-workers (3), who reported a 
noncompetitive partial model (meaning that F and F:I complexes have the same binding 
affinities for lysine). A possible reason for disagreement between research groups in reporting 
kinetic models is in the different approaches to kinetic data analysis. While a pure 
noncompetitive partial model provides a decent fit with fewer variables, the mixed partial model, 
having additional coefficient α, has a better fit and statistical characteristics. To provide an 
unbiased approach to discrimination between kinetic models, we found it useful to plot the 
kinetic data in Cornish-Bowden and Dixon plots and determine their inhibition patterns. 
Therefore uncompetitive and mixed models were selected for further kinetic analysis. Although 
this approach has been known for full types of inhibition (for which it is definitely more 
accurate), we have applied it to the case of partial inhibition. Straight plots can be obtained at 
inhibitor concentrations which precede the saturating region.  
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We found that lysine binds to the enzyme cooperatively and therefore cooperativity 
coefficients of lysine were calculated. The average cooperativity coefficients were found by 
graphical methods (2.8 ± 0.2) and cooperativity was also calculated as a result of global fitting 
(2.6 ± 0.1, 2.3 ± 0.2, 2.8 ± 0.2, Table 2.2). The results obtained by different methods are in a 
good agreement. This highly cooperative manner of binding cannot be ignored while fitting the 
experimental data, therefore concentrations of inhibitor and inhibition constants in the rate 
equations must be raised to the power of cooperativity coefficients (4). Atkinson et al. (5), who 
studied lysine inhibition kinetics of DHDPS from V. vinifera came to the same conclusion. The 
rate equations, modified with cooperativity coefficients, were successfully used in studying the 
kinetics of DHDPS inhibition by R,R-bislysine, as well as lysine inhibition of H56A and H56N. 
An interesting feature, lysine-induced ASA cooperativity, was noticed not only for wild-type 
DHDPS, but also for H56A and H56N mutants. To our knowledge this observation is rare, 
although there is precedent in the literature (6).  
L-Thialysine and α-methyl-DL-lysine are very weak inhibitors of DHDPS. Despite small 
structural differences between lysine and L-thialysine, the latter is a much poorer inhibitor. To 
find the exact reason for this decreased inhibitory activity of L-thialysine is one of the subjects of 
future work. Possibly, changes in pKa of the - and terminal amino groups, as well as carboxyl 
group of L-thialysine results in weaker hydrogen bonding between L-thialysine and residues of 
the allosteric site. On the other hand, the thioether fragment in L-thialysine is larger than the 
corresponding methylene group in lysine, and therefore unfavourable steric interactions with 
amino acid residues of the allosteric site can be the reason of weaker inhibitory activity of L-
thialysine. If the last statement is valid, then this can be a serious obstacle for future inhibitor 
design to introduce bulky aromatic rings in the inhibitor structure instead of lysine or R,R-
bislysine side chains (design of new inhibitors of DHDPS is discussed in section 5.3). The 
overlay of the crystal structures of L-lysine and L-thialysine bound at the allosteric site of C. 
jejuni DHDPS is shown in Figure 5.1.  
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Figure 5.1  Overlay of crystal structures of L-lysine (orange) and L-thialysine (green) bound 
at the allosteric site of C. jejuni DHDPS. (A) Position of overlaid ligands in the allosteric pocket; 
(B) The same overlay rotated 90°. 
The α-methyl group in α-methyl-DL-lysine prevents proper binding of the inhibitor at the 
adjacent lysine binding pockets in the allosteric site of DHDPS, therefore correct spacing 
between two inhibitor molecules or between binding fragments within a symmetrical molecule of 
inhibitor is required. The inhibition tests with α-methyl-DL-lysine suggest indirectly that the 
allosteric site of DHDPS will not tolerate homologs of R,R-bislysine with three- or four-carbon 
bridges in the structure. 
The design of R,R-bislysine was based on the hypothesis that a symmetrical molecule, 
targeting two lysine binding pockets in the allosteric site, would have an energy benefit as a 
result of the decrease in binding entropy. The principle of using one inhibitor molecule to target 
multiple protein sites has been used before and discussed in the literature. There are inhibitors, 
binding within one protein subunit, but targeting two receptor sites, such as vorinostat, a histone 
deacetylase inhibitor, where the two amide groups in the inhibitor were linked together with a 
spacer, resulting in stronger binding due to a chelating effect (7). There are also bisubstrate 
inhibitors, which mimics binding of two substrates to an enzyme using a linker. For instance, 
Shen et al. reported a peptide-ATP conjugate against insulin receptor kinase which occupied 
both peptide and nucleotide binding sites (8). Bisubstrate analogue inhibitors of 6-
hydroxymethyl-7,8-dihydropterin pyrophosphokinase were developed by placing a piperidine-
containing linkage between pterin and adenosine moieties (9). Another example of bisubstrate 
inhibitors is the estradiol/adenosine hybrid EM-1745 which is potent against 17b-hydroxysteroid 
dehydrogenase (10). Bivalent or polyvalent inhibitors are able to target two or more protein 
subunits by one inhibitor molecule. As an example, the carbohydrate ligand (STARFISH) was 
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designed against Shiga-like toxin I with subnanomolar inhibitory activity (11). The inhibitor 
coordinates with five protein subunits and has a million times higher inhibitory activity than that 
of univalent ligands (11). Applying the concept of bivalent inhibitor design, Duggineni et al. 
synthesized several dimeric peptides capable of binding simultaneously to two EphA2 receptor 
molecules, and this strategy resulted in an increase of binding affinity of these ligands (12). The 
result of using bisubstrate, bivalent or polyvalent inhibitors instead of univalent inhibitors 
depends on various factors including proper spacing of the moieties of the complex inhibitor. An 
optimal linker would provide a favourable conformation and promote a correct positioning of 
functional groups of the inhibitor with the protein molecule(s). The design of linked inhibitors 
has entropy advantages, moreover a linker part can also participate in hydrogen bonding, which 
would also result in a favourable enthalpy change (9).  
R,R-bislysine is an example of a divalent inhibitor, in that one molecule targets two protein 
subunits. The results of this work show that the strategy of inhibitor design is valid and we 
observed more than 300 times stronger inhibition of wild-type C. jejuni DHDPS by R,R-bislysine 
than by L-lysine, where the average inhibition constant of R,R-bislysine is 200 nM. The two-
carbon bridge in R,R-bislysine structure is optimal to allow the molecule to bind in the two 
adjacent lysine binding pockets, providing 3.93 Å distance between α-carbons, mimicking the 
enzyme-lysine structure nearly perfectly. R,R-bislysine demonstrates a slow-binding inhibition 
behaviour, where equilibrium between the inhibitor and the enzyme establishes within 1-1.5 min 
after mixing. The frequency constant of the exponential phase, kobs, has a linear relationship with 
the concentration of R,R-bislysine, which is an indication that R,R-bislysine binds slowly to the 
enzyme species, without enzyme isomerisation, which is also confirmed by crystallography 
results. Unlike L-lysine, R,R-bislysine binds to the free form of enzyme E, and therefore the 
mixed partial model of inhibition with respect to pyruvate provides the best fit to the 
experimental data. With respect to ASA, R,R-bislysine was found to be a noncompetitive partial 
inhibitor. Binding of R,R-bislysine to all forms of enzyme (except free form of enzyme, E) is 
cooperative and cooperativity coefficients were found to be 1.6 and 1.7 (Table 3.1), which 
indicates a highly cooperative manner of binding of R,R-bislysine to the dimeric subunits in the 
tetramer. The noncompetitive nature of R,R-bislysine is also beneficial when compared with 
competitive inhibitors, such that high concentrations of substrates cannot compete with the 
inhibitor for the binding site. 
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To explore the inhibitory potential of R,R-bislysine and L-lysine, the allosteric site of DHDPS 
was modified by Y110F, H56A, H56N, H59A and H59N mutations. The expectations were that 
mutations would decrease the binding affinity of inhibitors to a certain extent. Surprisingly, this 
prediction turned out to be valid only for lysine, but not for R,R-bislysine. Thus, Y110F, H59A 
and H59N were almost insensitive to lysine inhibition, and H56A and H56N were five- and 
three- times respectively less sensitive to lysine than the wild-type. Unlike lysine, R,R-bislysine 
showed exceptional inhibitory properties against Y110F, H56A, H56N and H59N mutants, with 
apparent IC50 values in the submicromolar range. These studies revealed, however, that binding 
of R,R-bislysine is dependent on His59. The H59A mutation, which eliminated hydrogen 
bonding between the terminal amino groups of R,R-bislysine and the histidines in the allosteric 
site, caused an approximately ten-fold increase in the apparent IC50 value. 
 
5.2 Design of new symmetrical inhibitors of DHDPS 
The results of this study now open new perspectives in the development of noncompetitive 
inhibitors of DHDPS. The strategy of designing symmetrical inhibitors targeting two lysine 
pockets in the allosteric site was shown to be successful. R,R-bislysine inhibition studies with 
mutants allows us to conclude that hydrogen bonding between the carboxyl group of the inhibitor 
and Tyr110 is not crucial for inhibitory effectiveness, whereas a hydrogen bond between His59 
and the ε-amino group of the inhibitor is essential, as was indicated previously. The importance 
of the α-amino groups in R,R-bislysine for inhibition is the subject for future work. Modification 
of R,R-bislysine is necessary for designing drug-like compounds, which are able to pass through 
bacterial cell walls. This optimization could include the replacement of carboxyl groups with 
suitable isosteres, design of a new spacer instead of the two-carbon bridge, which would fix the 
molecule in favorable conformation and reduce the number of rotatable bonds, introduce 
aromatic rings to the structure to increase lipophilicity, etc. The activity of R,R-bislysine against 
mutants of C. jejuni DHDPS, which are insensitive to lysine inhibition, means that R,R-bislysine 
would also likely be active against DHDPS from different species with a similar architecture of 
allosteric sites. The validity of this statement would be interesting to verify in future studies. 
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5.3 DHDPS from Gram-positive bacteria: inhibition of difficult targets 
It is a difficult task to inhibit lysine-insensitive DHDPS from Gram-positive bacteria. The 
major obstacle preventing binding of lysine and its mimics is Lys (or Arg) in position 56 (H59 in 
C. jejuni DHDPS). As discussed above, substitution of His59 for Ala in C. jejuni DHDPS 
resulted in tenfold decrease in inhibitory activity of R,R-bislysine. Therefore a favorable 
interaction of the amino acid residue in this position with the inhibitor is important for signal 
transduction from the allosteric to active site. Lys56 in DHDPS from Gram-positive bacteria 
prevents binding of L-lysine due to a steric clash and repulsion of positively charged Lys56 and 
the ε-amino group of the inhibitor. R,R-bislysine would have the same unfavorable interactions 
with the enzyme. For that reason a symmetrical molecule, having the same 2,5-diamino adipic 
acid scaffold as has R,R-bislysine, but with shorter side chains and polar, non-positively charged 
functional groups at the end of side chains would be a good candidate for preliminary studies of 
inhibition of DHDPS from Gram-positive bacteria.   
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APPENDIX A  
 
Figure A 1  Calibration plot for sodium bromide.  
Table A 1  Calculated amounts of sodium bromide in the samples. 
# Sample 
Sample concentration, 
mg/ml 
NaBr peak 
area 
% NaBr (w/w) 
1 R,R-bislysine 1.5 365.8 16 
2 S,S-bislysine 1.2 423.6 20 
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Figure A 2  An inhibition curve of DHDPS by R,R-bislysine (at 2.6 mM of ASA and 3.7 mM 
of pyruvate).  
 
 
Figure A 3  Progress curves of the enzymatic reaction: () in the absence of R,R-bislysine; in 
the presence of R,R-bislysine (0.84 µM): () reaction started with DHDPS, () reaction started 
with ASA. Concentrations of substrates: ASA 0.16 mM, pyruvate 3.7 mM.   
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Scheme A 1  A general equilibrium scheme for noncompetitive (including pure noncompetitive 
and mixed) partial inhibition (similar to the noncompetitive inhibition mechanism reported by 
Cha (Cha, S. (1975) Tight-binding inhibitors-I. Kinetic behavior, Biochem Pharmacol 24, 2177-
2185). Assumptions: KM >> Ki, k-1 >> k-3, k-1 >> k-4, k1S >> k3I, k1S >> k4I. Definitions: KM = (k-1 
+ k2)/k1; KMʹ = (k-5 + k6)/k5; Ki1 = k-3/k3, Ki2 = k-4/k4.  
Equation A1  The equation shows linear relationship between kobs and [I], and can be expressed 
in a linear form kobs = kon[I] + koff at constant concentration of [S], where kon and koff are apparent 
microscopic rate constants, which represent a slope and an intercept of the linear plot. 
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Figure A 4 Overlay of crystal structures C. jejuni DHDPS with L-lysine (magenta) and R,R-
bislysine (green) (Conly et al., Unpublished work). 
 
111 
 
   
  
Figure A 5  Hill plots at 3.7 mM pyruvate and varied concentrations of ASA: (A) 0.066 mM, 
(B) 0.099 mM, (C) 0.16 mM, (D) 0.33 mM, and (E) 2.6 mM. Solid lines were obtained by linear 
regression.  
   
  
Figure A 6  Hill plots at 2.6 mM ASA and varied concentrations of pyruvate: (A) 0.20 mM, 
(B) 0.30 mM, (C) 0.60 mM, (D) 1.0 mM, and (E) 3.7 mM. Solid lines were obtained by linear 
regression. 
 
y = -1.71x - 6.35 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.77x - 6.62 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.62x - 5.97 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
i s
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.76x - 6.54 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.46x - 5.53 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i 
- 
V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.62x - 6.17 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.70x - 6.44 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.69x - 6.23 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.68x - 6.35 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
y = -1.44x - 5.43 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-6 -4 -2 0 
lo
g
((
V
i -
 V
is
a
t)
/(
V
o
 -
 V
i)
) 
logI 
A B C 
D E 
A B C 
D E 
112 
 
 
Figure A 7  Residuals for plot in Figure 3.10.  
 
Figure A 8  Residuals for plot in Figure 3.11. 
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Spectrum A1-1  500 MHz 
1
H NMR spectrum of methyl (2S)-2,6-diaminohexanoate (1) in 
D2O. 
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Spectrum A2-1  500 MHz 
1
H NMR spectrum of methyl (2S)-2,6-bis{[(tert-
butoxy)carbonyl]amino}hexanoate (2) in CDCl3. 
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Spectrum A3-1  500 MHz 
1
H NMR spectrum of methyl (±)-2,6-bis{[(tert-
butoxy)carbonyl]amino}-2-methylhexanoate (3) in CDCl3. 
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Spectrum A3-2  125 MHz 
13
C NMR spectrum of methyl (±)-2,6-bis{[(tert-
butoxy)carbonyl]amino}-2-methylhexanoate (3) in CDCl3. 
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Spectrum A4-1  500 MHz 
1
H NMR spectrum of methyl (±)-2,6-diamino-2-methylhexanoic 
acid (4) in D2O. 
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Spectrum A4-2  125 MHz 
13
C NMR spectrum of methyl (±)-2,6-diamino-2-
methylhexanoic acid (4) in D2O. 
 
119 
 
 
Spectrum A5-1 500 MHz 
1
H NMR spectrum of dimethyl 2,5-dibromohexanedioate (5) in 
CDCl3 
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Spectrum A5-2 125 MHz 
13
C NMR spectrum of dimethyl 2,5-dibromohexanedioate (5) in 
CDCl3 
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Spectrum A6-1  500 MHz 
1
H NMR spectrum of dimethyl 2,5-bis(1,3-dioxo-2,3-dihydro-
1H-isoindol-2-yl)hexanedioate (6) in CDCl3. 
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Spectrum A6-2  125 MHz 
13
C NMR spectrum of 1,6-dimethyl-2,5-bis(1,3-dioxo-2,3-
dihydro-1H-isoindol-2-yl)hexanedioate (6) in CDCl3. 
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Spectrum A7-1  500 MHz 
1
H NMR spectrum of 2,5-diaminohexanedioic acid (7) in 
MeOD. 
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Spectrum A7-2  125 MHz 
13
C NMR spectrum of 2,5-diaminohexanedioic acid (7) in 
MeOD. 
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Spectrum A8-1   500 MHz 
1
H NMR spectrum of dimethyl 2,5-diaminohexanedioate 
dihydrochloride (8) in MeOD. 
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Spectrum A8-2    125 MHz 
13
C NMR spectrum of dimethyl 2,5-diaminohexanedioate 
dihydrochloride (8) in MeOD. 
 
127 
 
 
Spectrum A9-1    500 MHz 
1
H NMR spectrum of dimethyl 2,5-bis([(tert-
butoxy)carbonyl]amino)hexanedioate (9) in CDCl3. 
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Spectrum A9-2     125 MHz 
13
C NMR spectrum of dimethyl 2,5-bis([(tert-
butoxy)carbonyl]amino)hexanedioate (9) in CDCl3. 
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Spectrum A10-1     500 MHz 
1
H NMR spectrum of mixture of dimethyl (2R, 5R)-2,5-
bis([(tert-butoxy)carbonyl]amino)-2,5-bis(4-chlorobutyl)hexanedioate and dimethyl (2S, 5S)-2,5-
bis([(tert-butoxy)carbonyl]amino)-2,5-bis(4-chlorobutyl)hexanedioate (10a) in CDCl3. 
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Spectrum A10-2     125 MHz 
13
C NMR spectrum of mixture of dimethyl (2R, 5R)-2,5-
bis([(tert-butoxy)carbonyl]amino)-2,5-bis(4-chlorobutyl)hexanedioate and dimethyl (2S, 5S)-2,5-
bis([(tert-butoxy)carbonyl]amino)-2,5-bis(4-chlorobutyl)hexanedioate (10a) in CDCl3. 
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Spectrum A10-3     500 MHz 
1
H NMR spectrum of dimethyl (2R, 5S)-2,5-bis([(tert-
butoxy)carbonyl]amino)-2,5-bis(4-chlorobutyl)hexanedioate (10b) in CDCl3. 
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Spectrum A10-4     125 MHz 
13
C NMR spectrum of dimethyl (2R, 5S)-2,5-bis([(tert-
butoxy)carbonyl]amino)-2,5-bis(4-chlorobutyl)hexanedioate (10b) in CDCl3. 
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Spectrum A11-1     500 MHz 
1
H NMR spectrum of mixture of dimethyl (2R, 5R)-2,5-
bis([(tert-butoxy)carbonyl]amino)-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-
yl)butyl]hexanedioate and dimethyl (2S, 5S)-2,5-bis([(tert-butoxy)carbonyl]amino)-2,5-bis[4-
(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate (11) in CDCl3. 
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Spectrum A11-2    125 MHz 
13
C NMR spectrum of mixture of dimethyl (2R, 5R)-2,5-
bis([(tert-butoxy)carbonyl]amino)-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-
yl)butyl]hexanedioate and dimethyl (2S, 5S)-2,5-bis([(tert-butoxy)carbonyl]amino)-2,5-bis[4-
(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate (11) in CDCl3. 
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Spectrum A12-1    500 MHz 
1
H NMR spectrum of mixture of (2R, 5R)-2,5-diamino-2,5-
bis(4-aminobutyl)hexanedioate tetrabromide and (2S, 5S)-2,5-diamino-2,5-bis(4-
aminobutyl)hexanedioate tetrabromide (12) in D2O. 
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Spectrum A12-2     125 MHz 
13
C NMR spectrum of mixture of (2R, 5R)-2,5-diamino-2,5-
bis(4-aminobutyl)hexanedioate tetrabromide and (2S, 5S)-2,5-diamino-2,5-bis(4-
aminobutyl)hexanedioate tetrabromide (12) in D2O. 
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Spectrum A13-1    500 MHz 
1
H NMR spectrum of mixture of dimethyl (2R, 5R)-2,5-
diamino-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate and dimethyl 
(2S, 5S)-2,5-diamino-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate (13) 
in MeOD. 
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Spectrum A13-2    125 MHz 
13
C NMR spectrum of mixture of dimethyl (2R, 5R)-2,5-
diamino-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate and dimethyl 
(2S, 5S)-2,5-diamino-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate (13) 
in MeOD
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APPENDIX B  
Figure B 1  Sequence alignment of DHDPS from some Gram-negative bacteria
a
. 
E.coli                ---------MFTGSIVAIVTPMDEKGNVCRASLKKLIDYHVASGTSAIVSVGTTGESATL 51 
C.jejuni              --SNAMDKNIIIGAMTALITPFK-NGKVDEQSYARLIKRQIENGIDAVVPVGTTGESATL 57 
N.meningitidis        ---GIDPFTMLQGSLVALITPMNQDGSIHYEQLRDLIDWHIENGTDGIVAVGTTGESATL 57 
S.meliloti            ---------MFEGSITALVTPFA-DDRIDEVALHDLVEWQIEEGSFGLVPCGTTGESPTL 50 
R.typhi               ------MYNIFKGLITALITPFK-NNKLDLYAFESILNQQIKHEVDAVLIAGSTGEANSL 53 
Y.enterocolitica      ---------MFTGSIVALITPMDDKGNVDRASLKKLIDYHVASGTAAIVSVGTTGESATL 51 
A.baumannii           ---------TIQGSIVAIVTPMLKDGGVDWKSLEKLVEWHIEQGTNSIVAVGTTGEASTL 51 
M.alcaliphilum        ---------MIQGSIVALVTPMMENGSIDKDSLKKLIEFHIDQGTDSIVAVGTTGESATL 51 
M.mediterranea        ---MNKLRSRFTGVFTALVTPFR-DGSIDFVAFDALVERQIAAGVAGLVPVGTTGEAATL 56 
B.marinus             -----MN-LNDYKLWTAVITPMKEDGSVNYDDLTNVLRDQ-EAAKNGILILGSTGEALNL 53 
X.albilineans         --------MSFSGIITALATPFQSNGDLDLDAWQRLLKRQLEGGVQGVVVAGSTGEAATL 52 
N.indicus             MTTMNELANRFKGVFTALVTPFR-DGAVDYAAYDALVERQLAAGVAGLVPVGTTGEAATL 59 
H.ducreyi             ---MIMSVPLFHGSIVALLTPMT-HGEVNYQEIKNLVEYHIQAGSHGIVAMGTTGESTTL 56 
H.arsenicoxydans      ---------MIQGSIVAIVTPMHADGALDLPGLRKLIDWHIAEGTDGIVIVGTTGESPTV 51 
                                     .*: **:  .  :       ::  :      .::  *:***: .: 
 
E.coli                NHDEHADVVMMTLDLADG-RIPVIAGTGANATAEAISLTQRFNDSGIVGCLTVTPYYNRP 110 
C.jejuni              THEEHRTCIEIAVETCKGTKVKVLAGAGSNATHEAVGLAKFAKEHGADGILSVAPYYNKP 117 
N.meningitidis        SVEEHTAVIEAVVKHVAK-RVPVIAGTGANNTVEAIALSQAAEKAGADYTLSVVPYYNKP 116 
S.meliloti            SKSEHEQVVEITIKTANG-RVPVIAGAGSNSTAEAIAFVRHAQNAGADGVLIVSPYYNKP 109 
R.typhi               SFEEYKLLLKTSVEIVNN-RMPIISGCSSNNTAYAIELAIASKKIGVDGFMASPPSYVKP 112 
Y.enterocolitica      NHDEHVDVVLQTLELADG-RIPVIAGTGANATSEAISLTQRFNDTGVVGCLTVTPYYNRP 110 
A.baumannii           SMEEHTQVIKEIIRVANK-RIPIIAGTGANSTREAIELTKAAKDLGADAALLVTPYYNKP 110 
M.alcaliphilum        DEDEHCDFIKSVVDYAGG-RIPIIAGTGANSTTEAIELTKRAKEVGADACLLVTPYYNKP 110 
M.mediterranea        SDDEADQLIARTVEKTKG-RALVMAGAGANDTKKAVEKIRRAEAAGADAVLVVTPYYNKP 115 
B.marinus             DEDEKVKILEHTLSLNL--TSPIMVGVGGINLTDTVKWIDYLETLPVHCYLLVTPLYAKP 111 
X.albilineans         LDDEYDLLMREAVGAIGG-RVPVLAGTGLSGTAKTVALTRRAAANGAQYALVVTPPYVRP 111 
N.indicus             SDEEAEELIARTVRLASG-RALVMAGAGANDTSKTVDKVKRAERAGADALLIVTPYYNKP 118 
H.ducreyi             SIDEHVKVIKKTVEFADG-RIPIIAGSGSNATSEAVTITKLLNGVGVVGCLSVVPYYNKP 115 
H.arsenicoxydans      SVDEHCELIRVAVEHTAK-RIPIIAGTGGNSTSEAIELTQFAKDVGADASLQVVPYYNRP 110 
                        .*    :   :         :: * .      ::              :   * * :* 
 
E.coli                SQEGLYQHFKAIAEHTDLPQILYNVPSRTGCDLLPETVGRLA-KVKNIIGIKEATGNLTR 169 
C.jejuni              TQQGLYEHYKAIAQSVDIPVLLYNVPGRTGCEISTDTIIKLFRDCENIYGVKEASGNIDK 177 
N.meningitidis        SQEGIYQHFKTIAEATSIPMIIYNVPGRTVVSMTNDTILRLA-EIPNIVGVKEASGNIGS 175 
S.meliloti            TQEGIYQHFKAIDAASTIPIIVYNIPGRSAIEIHVETLARIFEDCPNVKGVKDATGNLLR 169 
R.typhi               TQHGIYKHFEALHEACNLPIMLYSAPTRSGVDFSDETILRLS-KLPRILALKDCGVDLER 171 
Y.enterocolitica      MQEGLYQHFKAIAESTDLPQILYNVPSRTGCDMLPPTIARLA-KIKNIVAVKEATGNLSR 169 
A.baumannii           TQEGLYQHYKAIAEAVELPLILYNVPGRTGVDLSNDTAVRLA-EIPNIVGIKDATGDVPR 169 
M.alcaliphilum        TQEGLYLHFKVVAEAVDIPQILYNVPGRTACDMLPETVARLS-VIDNIVGIKEASGKLER 169 
M.mediterranea        TQAGLIAHYGAVAGATALPVMLYSVPGRCGVEIAPETCATLMRKHANIFSIKEAGGSAAR 175 
B.marinus             GTVGQYEWFKTLLDDSSRPCMLYNVPGRTGVKMSFEAIELLK-DHKNFWAIKEASGSTED 170 
X.albilineans         TQAGLLAHYTQVAEQGGLPVVLYNVPSRTGCDLLPETVARLA-QHPAIVGIKEASSDPQR 170 
N.indicus             TQEGLIAHYGAAAEATGLPIMLYSVPGRCGVEIAPETCATLMQRHSNIVAMKEAGGDAGR 178 
H.ducreyi             TQEGLYLHYKAIAESTELPQILYNVPSRTGCDLKPETIGRLS-EIPNIIGVKEATGDLTR 174 
H.arsenicoxydans      TQEGMYQHFKKIVEAVDLPAILYNVPGRTVADMSNETILRLA-QIPSVIGVKDATGNISR 169 
                         *    :         * ::*. * *   .:   :   :      . .:*:.  .    
 
E.coli                VNQIKELVS-DDFVLLSGDDASALDFMQLGGHGVISVTANVAARDMAQMCKLAAEGHFAE 228 
C.jejuni              CVDLLAHE--PRMMLISGEDAINYPILSNGGKGVISVTSNLLPDMISALTHFALDENYKE 235 
N.meningitidis        NIELINRAP-EGFVVLSGDDHTALPFMLCGGHGVITVAANAAPKLFADMCRAALQGDIAL 234 
S.meliloti            PSLERMACG-EDFNLLTGEDGTALGYMAHGGHGCISVTANVAPALCADFQQACLNGDFAA 228 
R.typhi               PMRIRAIVK-EDFNILTGNDEVVLAFHAQGVIGWISVTSNIAPKICKELLDKWYNNDIQG 230 
Y.enterocolitica      VSQIQVLVDDEDFILLSGDDASGLDFMQLGGQGVISVTANIAAREMVELCALAAQGNFAE 229 
A.baumannii           GKALIDALN-GKMAVYSGDDETAWELMLLGADGNISVTANIAPKAMSEVCAVAIAKDEQQ 228 
M.alcaliphilum        VKRLRDLCG-EKFALYTGDDATSCEFCLLGGNGTITVTGNVAPRLVHEMITAAIDGDRET 228 
M.mediterranea        VSELRRACG-DELIVHSGDDGLTLPFLSLGAVGVTSVVANVAPDTMVAMVRAWHEGNTAH 234 
B.marinus             FSKYVKAA--PGAMVYSGDDAMLPDYTPLGAKGLVSVASNVWAKQTHNYVQKALSNELNE 228 
X.albilineans         IAALVALRS-EHFAVLSGDDGSAAQAMLSGFDGLISVASNALPGAYRHLCDLARAQQAEP 229 
N.indicus             VTRLRQACG-ESLIIHSGDDGLTLPFLSLGALGVTSVVANVAPGEMVRMVEAWQRGETTR 237 
H.ducreyi             LPLIKTLAG-EDFIFLSGDDATGLESMKLGGQGVISVTNNLAAADMAKMCELVLAGNFAE 233 
H.arsenicoxydans      GIDLMRLRP-KDFAVYSGDDATAMALMLCGANGNISVTANIAPRGMHQLCDAAINQRVAE 228 
                                    . :*:*         *  *  :*. *                     
a
 Catalytic triad is shown in green, a key residue Lys is shown in cyan, the conserved arginine is shown in 
magenta, selected residues of the allosteric site are shown in yellow. 
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Figure B 2  Sequence alignment of DHDPS from some plants
a
. 
V.vinifera        LPMRSFEVKNRTSVDDIKSLRLITAIKTPYLPDGRFDLEAYDALVNMQIVDGAEGVIVGG 87 
N.sylvestris      -----------TFADDIKALRLITAIKTPYLPDGRFDLEAYDTLVNLQIENGAEGVIVGG 49 
Z.mays            LPMRSTEVKNRTLTGDITSLRLITAVKTPYLPDGRFDLEAYDSLINMQIEGGSEGVIVGG 118 
Z.latifolia       --MRSSEVKNRTSTADITSLRLITAVKTPYLPDGRFDLEAYDSLINMQVDGGAEGVIVGG 58 
A.thaliana        LPMRSLEVKNRTNTDDIKALRVITAIKTPYLPDGRFDLEAYDDLVNIQIQNGAEGVIVGG 106 
T.aestivum        LPMRSTEVKNRTSVDGIKSLRLITAVKTPYLPDGRFDLEAYDSLINTQINGGAEGVIVGG 118 
T.cacao           LPMRSFEVKNRTSSEDIKSLRLITAIKTPYLPDGRFDLEAYDGLVNMQIENGAEGVIVGG 106 
O.sativa          LPMRSSEVKNRTSTGDITSLRVITAVKTPYLPDGRFDLEAYDSLINMQIEGGAEGVIVGG 88 
                             *    *.:**:***:**************** *:* *:  *:******* 
 
V.vinifera        TTGEGQLMSWDEHIMLIGHTVNCFGGSIKVIGNTGSNSTREAIHATEQGFAVGMHAALHI 147 
N.sylvestris      TTGEGQLMSWDEHIMLIGHTVNCFGGSIKVIGNTGSISTREAIHATEQGFAVGMHAALHI 109 
Z.mays            TTGEGHLMSWDEHIMLIGHTVNCFGTRIKVIGNTGSNSTREAVHATEQGFAVGMHAALHI 178 
Z.latifolia       TTGEGHLMSWDEHIMLIGHTVNCFGTKIKVIGNTGSNSTREAIHATEQGFAVGMHAALHI 118 
A.thaliana        TTGEGQLMSWDEHIMLIGHTVNCFGGSIKVIGNTGSNSTREAIHATEQGFAVGMHAALHI 166 
T.aestivum        TTGEGHLMSWDEHIMLIGHTVNCFGTNIKVIGNTGSNSTREAIHASEQGFAVGMHAALHV 178 
T.cacao           TTGEGQLMSWDEHIMLIGHTVNCFGGSIKVIGNTGSNSTREAIHATEQGFAVGMHAALHI 166 
O.sativa          TTGEGHLMSWDEHIMLIGHTVNCFGTKIKVVGNTGSNSTREAIHATEQGFAVGMHAALHI 148 
                  *****:*******************  ***:***** *****:**:*************: 
 
V.vinifera        NPYYGKTSLEGLVSHFESVLPMGPTVIYNVPSRTGQDIPPGVIHTVAQSANLAGVKECVG 207 
N.sylvestris      NPYYGKTSLEGLISHFESVLPMGPTIIYNVPSRTGQDIPPRVIQTMAKSPNLAGVKECVG 169 
Z.mays            NPYYGKVSTEGLISHFEAVLPMGPTIIYNVPSRSGQDIPPQVIETLSGYPNMAGVKECVG 238 
Z.latifolia       NPYYGKTSIEGLISHFEAVLPMGPTIIYNVPSRTGQDIPPAVIEAVSSFSNMAGVKECVG 178 
A.thaliana        NPYYGKTSIEGLIAHFQSVLHMGPTIIYNVPGRTGQDIPPRAIFKLSQNPNLAGVKECVG 226 
T.aestivum        NPYYGKTSTAGLISHFDEVLPMGPTIIYNVPSRTGQDIPPAVIEALSTYPNMAGVKECVG 238 
T.cacao           NPYYGKTSLEGLVSHFDSVLPMGPTIIYNVPSRTGQDIPPRVINTVAQSPNLAGVKECVG 226 
O.sativa          NPYYGKTSVEGLISHFEAVLPMGPTIIYNVPSRDWQDIPPPVIEAVSSYTNMAGVKECVG 208 
                  ******.*  **::**: ** ****:*****.*  ***** .*  ::   *:******** 
 
V.vinifera        NDRIKQYTDNRIVVWSGNDDQCHDAKWDYGATGVISVTSNLIPGLMRQLLFKGKNPSLNA 267 
N.sylvestris      NDRVEQYTSNGIVVWSGNDDECHVSRWDYGATGVISVTSNLVPGLMRELMFGGKNLALNS 229 
Z.mays            HERVKCYTDKGITVWSGNDDECHDSRWKYGATGVISVASNLVPGLMRSLMYEGENALLNE 298 
Z.latifolia       HERVKCYTDKGITIWSGNDDECHDSRWKHGATGVISVASNLVPGLMHNLMYEEQTAVLNE 238 
A.thaliana        NKRVEEYTENGVVVWSGNDDECHDSRWDYGATGVISVTSNLVPGLMRKLMFEGRNSSLNS 286 
T.aestivum        HERVKCYTDKGITIWSGNDDECHDSRWKYGATGVISVTSNLVPGLMRSLMFEGENAALNE 298 
T.cacao           NDRIEQYTDNGIVVWSGNDDQCHDARWSHGATGVISVTSNLIPGLMRELMFGGKNPSLNV 286 
O.sativa          HERVKCYADRGISIWSGNDDECHESRWKYGATGVISVASNLIPGLMHSLMYEGENAALND 268 
                  ..*:: *:.. : :******:** ::*.:********:***:****:.*::  ..  **  
 
V.vinifera        KIMPLVNWLFEEPNPIGLNTALAQLGVVRPVFRLPYVPLPLAKRVEFVNIVKEIGRENFV 327 
N.sylvestris      KLMPLVEWLFHEPNPIALNTAFAQLGVVRPVFRLPYVPLTKAKREEFVKIVKDIGRENFI 289 
Z.mays            KLLPLTKWLFCLPNPIALNTALAQLGVARPVFRLPYVPLPLEKRIEFVRIVEAIGRGNFV 358 
Z.latifolia       KLLPLMKWLFCQPNPIALNTALAQLGVVRPVFRLPYVPLPREKRVEFVRIVESIGRENFV 298 
A.thaliana        KLLPLMAWLFHEPNPIGINTALAQLGVSRPVFRLPYVPLPLSKRLEFVKLVKEIGREHFV 346 
T.aestivum        KLLPLMKWLFSEPNPIGLNTALAQLGVVRPVFRRPYAPLSLEKRTEFVRIVEAIGRENFV 358 
T.cacao           KLLPLIEWLFEEPNPIGLNTALAQLGVVRPVFRLPYVPLPLAKRVEFVNLVRQIGRQNFV 346 
O.sativa          KLLPLMKWLFCQPNPIALNTALAQLGVARPVFRLPYVPLPLEKRVEFVRIVESIGRENFV 328 
                  *::**  ***  ****.:***:***** ***** **.**   ** ***.:*. *** .*: 
 
a
 Catalytic triad is shown in green, the key residue Lys is shown in cyan, the conserved arginine is shown in 
magenta, selected residues of the allosteric site are shown in yellow. 
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Figure B 3  Sequence alignment of DHDPS from some Gram-positive bacteria
a
. 
 
B.anthracis       -------------MIDFGTIATAMVTPFDINGNIDFAKTTKLVNYLIDNGTTAIVVGGTT 47 
S.aureus_m.r      -------------THLFEGVGVALTTPFTN-NKVNLEALKAHVNFLLENNAQAIIVNGTT 46 
C.glutamicum      MAITSTGLTAKTGVEHFGTVGVAMVTPFTESGDIDIAAGREVAAYLVDKGLDSLVLAGTT 60 
L.ruminis         ------------MDLKNSHIMTAMVTPFDKDGNVDYELLKRLIDHLLSTGTDGILVSGTT 48 
C.botulinum       --------------SIFKGSGVAIITPFTN-TGVDFDKLSELIEWHIKSKTDAIIVCGTT 45 
S.salivarius      ---------MSIDQLRDVKLITALITPFHEDGSINYDALPELIEHLLAHHTEALLLAGTT 51 
S.pneumoniae      ---------MSYQDLKECKIITAFITPFHEDGSINFDAIPALIEHLLAHHTDGILLAGTT 51 
L.garvieae        ---------------MLKGSIVALITPFNDDNSINFEKLAELIEFQISHGSAAISILGTT 45 
                                       .*: ***     ::           :     .: : *** 
 
B.anthracis       GESPTLTSEEKVALYRHVVSVVDKRVPVIAGTGSNNTHASIDLTKKATEV-GVDAVMLVA 106 
S.aureus_m.r      AESPTLTTDEKELILKTVIDLVDKRVPVIAGTGTNDTEKSIQASIQAKAL-GADAIMLIT 105 
C.glutamicum      GESPTTTAAEKLELLKAVREEVGDRAKLIAGVGTNNTRTSVELAEAAASA-GADGLLVVT 119 
L.ruminis         GEGPTLTEEEKIELIEKTVEYVAGRVPVVAGTGSNNTKTTIEYTNKVAKIDGVDAALVVV 108 
C.botulinum       GEATTMTETERKETIKFVIDKVNKRIPVIAGTGSNNTAASIAMSKWAESI-GVDGLLVIT 104 
S.salivarius      AESPTLTHDEELELFAAVQKIVNGRVPLIAGVGTNDTRDSIEFAKEVAKFGGFAAGLAIV 111 
S.pneumoniae      AESPTLTHDEELELFAAVQKVVNGRVPLIAGVGTNDTRDSIEFVKEVAEFGGFAAGLAIV 111 
L.garvieae        GEAPTISFEEKKAIVEFVVKQVAGRIHINVGAGSNNTAQAVEFAQAFEKL-GADSLLVIT 104 
                  .*. * :  *.      . . *  *  : .*.*:*:*  ::          *  . : :. 
 
B.anthracis       PYYNKPSQEGMYQHFKAIAESTPLPVMLYNVPGRSIVQISVDTVVRLSEIENIVAIKDAG 166 
S.aureus_m.r      PYYNKTNQRGLVKHFEAIADAVKLPVVLYNVPSRTNMTIEPETVEILSQHPYIVALKDAT 165 
C.glutamicum      PYYSKPSQEGLLAHFGAIAAATEVPICLYDIPGRSGIPIESDTMRRLSELPTILAVKDAK 179 
L.ruminis         PYYNKPDQAGMIAHFTAVADNVDLPIVMYNIPGRTGVTMEVKTIAELSKHQNIIGIKDCT 168 
C.botulinum       PYYNKTTQKGLVKHFKAVSDAVSTPIIIYNVPGRTGLNITPGTLKELCEDKNIVAVKEAS 164 
S.salivarius      PYYNKPSQEGMYQHFKAIADASDLPIIIYNIPGRVVVEMAPDTMLRLAEHPNIIGVKECT 171 
S.pneumoniae      PYYNKPSQEGMYQHFKAIADASDLPIIIYNIPGRVVVELTPETMLRLADHPNIIGVKECT 171 
L.garvieae        PYYNKTNETGMLKHFTKIAESVDIPIIMYNAPGRTGVNLSVEAVEVLAKHPNITGLKEAS 164 
                  ***.*  : *:  **  ::     *: :*: *.*  : :   ::  *..   * .: :.  
 
B.anthracis       GDVLTMTEIIE-KTADDFAVYSGDDGLTLPAMAVGAKGIVSVASHVIGNEMQEMIAAFQA 225 
S.aureus_m.r      NDFEYLEEVKKRIDTNSFALYSGNDDNVVEYYQRGGQGVISVIANVIPKEFQALYDAQQS 225 
C.glutamicum      GDLVAATSLIK-ET--GLAWYSGDDPLNLVWLALGGSGFISVIGHAAPTALRELYTSFEE 236 
L.ruminis         G-IVNMAEIVA-NTPDDFLAFTGEDADALAARNVGAQGVISVASHLFGKEISQMYAANSK 226 
C.botulinum       GNISQIAQIKA-LCGDKLDIYSGNDDQIIPILALGGIGVISVLANVIPEDVHNMCELYLN 223 
S.salivarius      S-LANMAYLIE-HKPEDFLVYTGEDGDAFHAMNLGANGVISVASHTNGDEMHAMLEAIEN 229 
S.pneumoniae      S-LANMAYLIE-HKPEEFLIYTGEDGDAFHAMNLGADGVISVASHTNGDEMHEMFTAIAE 229 
L.garvieae        GDIAYVEKISR-YLSNNFALYSGNDDMIVPCLSLGASGVISVWANFMPDVVKELIETFAT 223 
                    .     :        :  ::*:*   .     *. *.:** ..     .  :       
 
B.anthracis       GEFKKAQKLHQLL---VRVTDSLFMAPSPTPVKTALQMVGLDVGSVRLPLLPLTEEERVT 282 
S.aureus_m.r      G-----LDIQDQFKPIGTLLSALSVDINPIPIKALTSYLGFGNYELRLPLVSLEDTDTKV 280 
C.glutamicum      GDLVRAREINAKL---SPLVAAQGRLGGVSLAKAALRLQGINVGDPRLPIMAPNEQELEA 293 
L.ruminis         GDNELAGELMRDL---TPKMKALFSHPSPSPVKAALNHVGIEVGGCRLPILALDDAQASV 283 
C.botulinum       GKVNEALKIQLDS---LALTNALFIETNPIPVKTAMNLMNMKVGDLRLPLCEMNENNLEI 280 
S.salivarius      SDLKTAAAIQRKF---IPKVNALFSVPSPAPVKAVLNHLGFEVGPLRLPLVACTSEEAKR 286 
S.pneumoniae      SDMKKAAAIQRKF---IPKVNALFSYPSPAPVKAILNYMGFEAGPTRLPLVPAPEEDVKR 286 
L.garvieae        NP-AHSLSLQQKY---LNLIDSLFIEANPIPVKFVMNQLGYNVGSVRLPLDEPSETAKIQ 279 
                          :            :          *             ***:    .      
 
a
 Catalytic triad is shown in green, the key residue Lys is shown in cyan, the conserved arginine is shown in 
magenta, selected residues of the allosteric site are shown in yellow
a
. 
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Figure B 4  Double-reciprocal plots of the Y110F-catalyzed reaction. Solid lines are the 
global fit of Equation 4.1 to the data. (A) Concentration of pyruvate: (●) 0.15 mM, (○) 0.20 mM, 
(■) 0.30 mM, (□) 0.60 mM, (♦) 1.0 mM, (◊) 3.7 mM; (B) Concentration of ASA: (◊) 0.073 mM, 
(♦) 0.093 mM, (□) 0.14 mM, (■) 0.19 mM, (○) 0.37 mM, (●) 2.6 mM. 
 
 
Figure B 5  Residuals for plots in Figure B 4. 
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Figure B 6  Double-reciprocal plots of the H56A-catalyzed reaction. Solid lines are the global 
fit of Equation 4.1 to the data. (A) Concentration of ASA: (●) 2.5 mM, (○) 0.82 mM, (■) 0.49 
mM, (□) 0.16 mM, (♦) 0.098 mM, (◊) 0.066 mM; (B) Concentration of pyruvate: (◊) 0.15 mM, 
(♦) 0.20 mM, (□) 0.30 mM, (■) 0.60 mM, (○) 1.0 mM, (●) 3.7 mM. 
 
 
Figure B 7  Residuals for plots in Figure B 6. 
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Figure B 8  Double-reciprocal plots of the H56N-catalyzed reaction. Solid lines are the global 
fit of Equation 4.1 to the data. (A) Concentration of ASA: (●) 2.5 mM, (○) 0.76 mM, (■) 0.47 
mM, (□) 0.16 mM, (♦) 0.093 mM, (◊) 0.062 mM; (B) Concentration of pyruvate: (◊) 0.15 mM, 
(♦) 0.20 mM, (□) 0.30 mM, (■) 0.60 mM, (○) 1.0 mM, (●) 3.7 mM. 
 
 
Figure B 9  Residuals for plots in Figure B 8. 
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Figure B 10  Double-reciprocal plots of the H59A-catalyzed reaction. Solid lines are the global 
fit of Equation 4.1 to the data. (A) Concentration of ASA: (●) 2.4 mM, (○) 0.76 mM, (■) 0.46 
mM, (□) 0.15 mM, (♦) 0.10 mM, (◊) 0.064 mM; (B) Concentration of pyruvate: (♦) 0.15 mM, 
(□) 0.20 mM, (■) 0.60 mM, (○) 1.0 mM, (●) 3.7 mM. 
 
Figure B 11  Residuals for plots in Figure B 10. 
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Figure B 12  Double-reciprocal plots of the H56N-catalyzed reaction. Solid lines are the global 
fit of Equation 4.1 to the data. (A) Concentration of ASA: (●) 2.4 mM, (○) 0.76 mM, (■) 0.46 
mM, (□) 0.15 mM, (♦) 0.10 mM, (◊) 0.064 mM; (B) Concentration of pyruvate: (◊) 0.15 mM, 
(♦) 0.20 mM, (□) 0.30 mM, (■) 0.60 mM, (○) 1.0 mM, (●) 3.7 mM. 
 
Figure B 13  Residuals for plots in Figure B 12.  
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Figure B 14  Hill plots at 3.7 mM pyruvate and varied concentrations of ASA for H56A 
mutant: (A) 0.050 mM, (B) 0.099 mM, (C) 0.16 mM, (D) 0.25 mM, (E) 2.5 mM. Solid lines 
were obtained by linear regression. 
 
  
  
Figure B 15  Hill plots at 2.5 mM ASA and varied concentrations of pyruvate for H56A 
mutant: (A) 0.15 mM, (B) 0.25 mM, (C) 0.50 mM, (D) 1.0 mM, (E) 3.7 mM. Solid lines were 
obtained by linear regression. 
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Figure B 16  Hill plots at 3.7 mM pyruvate and varied concentrations of ASA for H56N 
mutant: (A) 0.062 mM, (B) 0.093 mM, (C) 0.16 mM, (D) 0.47 mM, (E) 2.5 mM. Solid lines 
were obtained by linear regression. 
 
   
   
Figure B 17  Hill plots of at 2.5 mM ASA and varied concentrations of pyruvate for H56N 
mutant: (A) 0.15 mM, (B) 0.20 mM, (C) 0.30 mM, (D) 0.60 mM, (E) 1.0, (F) 3.7 mM. Solid 
lines were obtained by linear regression. 
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Figure B 18  Hill plots at 3.7 mM pyruvate and varied concentrations of lysine for H56A 
mutant: (A) 0 mM, (B) 0.08 mM, (C) 0.10 mM, (D) 0.15 mM, (E) 0.20, (F) 0.50, (G) 5.0 mM. 
Solid lines were obtained by linear regression. (H) Plot n(ASA) vs. [L-lysine]  
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Figure B 19  Hill plots at 3.7 mM pyruvate and varied concentrations of lysine for H56N 
mutant: (A) 0 mM, (B) 0.08 mM, (C) 0.10 mM, (D) 0.15 mM, (E) 0.20, (F) 0.50 mM. Solid lines 
were obtained by linear regression. (G) Plot n(ASA) vs. [L-lysine]  
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Figure B 20  Residuals for plots in Figure 4.4. 
 
 
Figure B 21  Residuals for plots in Figure 4.5.  
 
  
Figure B 22  Residuals for plots in Figure 4.6.  
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Figure B 23  Residuals for plots in Figure 4.7. 
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